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The second mammalian isoform of GnRH (GnRH-II) has been linked to 
regulation of cell proliferation, feed intake, and the interaction between energy balance 
and reproductive behavior. In contrast to the native form of GnRH (GnRH-I), GnRH-II is 
an inefficient modulator of gonadotropin secretion. Unlike many species, a functional 
receptor (GnRHR-II) specific to this ligand has been discovered in the pig that may be 
directly involved in testosterone production. Therefore, our objective was to identify the 
role of GnRH-II and its receptor in testicular function. First, there was 6-fold more 
GnRHR-II protein in the testis than anterior pituitary gland of boars. GnRH-II levels 
determined by ELISA were highest in testis (1,321 pg/ml), intermediate in pituitary (393 
pg/ml) and lowest in hypothalamus (220 pg/ml) tissue homogenates. 
Immunohistochemistry indicated that the GnRHR-II was located on the plasma 
membrane of Leydig cells within the interstitium as well as germ cells. Second, 
immunocytochemistry demonstrated that GnRHR-IIs were localized to the neck region of 
spermatozoa. Consistent with this, GnRH-II was also detected in seminal plasma (225 
pg/ml). Third, testicular tissue explants exposed to GnRH-II secreted testosterone 
similarly to hCG treated tissues, without influencing GnRHR-II or LH receptor protein 
  
levels. Finally, 4 in vivo experiments were performed on boars surgically fitted with 
jugular cannulae. In Exp. 1, testosterone concentrations were elevated following 
treatment with either a
 
GnRH-I (D-ala
6 
GnRH-I) or GnRH-II (D-ala
6 
GnRH-II) agonist, 
although GnRH-II induced changes in LH levels were not correlated with testosterone 
production. In Exp. 2, treatment with a GnRH-I (SB-75) or GnRH-II (Trp-1) antagonist 
suppressed testosterone, but not LH, secretion.  In Exp. 3, testosterone concentrations 
increased after treatment with SB-75 followed by infusion of either
 
GnRH-I or -II, 
despite the inability of GnRH-II to induce LH secretion. In Exp. 4, intratesticular 
injection with GnRH-I, GnRH-II or saline resulted in GnRH-II-induced stimulation of 
testosterone production without increasing LH levels.  Thus, GnRH-II may directly 
impact testosterone production via binding to the GnRHR-II on Leydig cells, bypassing 
LH production by the anterior pituitary gland. 
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CHAPTER I 
 
INTRODUCTION 
 
Boar subfertility is a growing constraint of pork production (Dyck et al., 2011) 
and can impact industry profitability by reducing sow reproductive efficiency and 
increasing costs to boar studs. First, utilizing semen from subfertile boars can impact sow 
productivity as poor semen quality is detrimental to conception rates. For example, 
approximately 11.6 million sows farrowed in 2010 (USDA-NASS, 2010). Based on an 
estimated feed cost of $40.42 per sow from farrowing to weaning, a 5% reduction in 
conception rates could lead to $19.9 million spent feeding non-productive sows.  
Similarly, it is easy to predict the direct impact of decreasing average litter size, 
especially since 93% of the pig inventory is on farms raising at least 1,000 pigs (Levis, 
2000).  Thus, even a 0.2 decrease in number of piglets born alive could result in a 
$99,000 loss to a producer raising 10,000 sows. Second, male subfertility also results in 
economic losses within a boar stud. Subfertile boars likely contribute to fewer doses of 
semen sold per ejaculate compared to fertile boars, although input costs remain the same.  
Approximately 80% of swine producers utilize artificial insemination (AI), requiring 30 
million doses of boar semen annually (Kuster and  Althouse, 2008).  If the average cost 
per dose is $6.50, even a 1% increase in the number of available doses would provide an 
additional $2 million per year to US boar studs.  
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The population of subfertile boars is growing despite the use of screening 
methods to detect suboptimal samples (Dyck et al., 2011). The use of these conventional 
semen analyses (morphology, motility, concentration and seminal volume) is common in 
boar studs (Amann et al., 1995).  Although these methods are correlated with fertility 
(Flowers, 1997; Xu et al., 1998), many authors suggest that these parameters do not 
reflect the true fertility of a boar (Correa et al., 1997; Brahmkshtri et al., 1999). 
Therefore, compensation techniques have been developed in the industry to mask 
subfertile boars, despite passing standard semen screening (Dyck et al., 2011). 
Commonly, semen collections are pooled from multiple sires and AI doses packaged in 
excess of 3 billion sperm cells (Dyck et al., 2011). These techniques may yield acceptable 
conception rates but drastically reduce the efficiency of a stud operation.  Thus, there is a 
critical need to better understand testicular function in the boar. 
Recently, a new mammalian form of GnRH (GnRH-II) was discovered. 
Originally isolated in the chicken (Miyamoto et al., 1984), this decapeptide differs from 
native GnRH (GnRH-I) by 3 amino acids and is expressed in almost every tissue (Kasten 
et al., 1996; Millar, 2003).  GnRH-II can function through the GnRH-I receptor to 
activate signal transduction and it also binds its own specific receptor (GnRHR-II). 
Originally cloned and sequenced in catfish (Tensen et al., 1997), the GnRHR-II is also 
present in mammals and like GnRHR-I, is a 7-transmembrane, G-protein coupled 
receptor (Neill et al., 2001; Millar et al., 2001). However, unlike the GnRHR-I, this 
receptor contains an intracytoplasmic tail, characteristic of rapid receptor internalization 
(Ronacher et al., 2004). Moreover, not all species maintain the coding sequence to 
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produce a functional GnRHR-II due to frameshift mutations and premature stop codons 
(Morgan et al., 2003; Gault et al., 2004a; Stewart et al., 2009). Interestingly, the sequence 
for a functional receptor has been discovered in shrews, old world monkeys and swine 
(Stewart et al., 2009). In these species, the function of GnRH-II and its receptor is unclear 
(Neill et al., 2004) but evidence suggests that GnRH-II is not an efficient modulator of 
gonadotropin secretion (Okada et al., 2003). GnRH-II and its receptor have been linked to 
feed intake (Kauffman and  Rissman, 2004b), as well as the interaction between energy 
balance and sexual behavior in females (Kauffman and  Rissman, 2004a; Kauffman et al., 
2005; Kauffman et al., 2006).  Further, GnRH-II may regulate cell proliferation and 
apoptosis in peripheral reproductive tissues (Chou et al., 2002). In addition, new evidence 
suggests that GnRH-II might also be involved in male reproductive function.  
Bowen et al. (2006) discovered that boars immunized against GnRH-II displayed 
reduced levels of testosterone independent of alterations in gonadotropin secretion. 
Similarly, primary Leydig cell cultures from GnRH-II immunized boars secreted less 
testosterone compared to control boars upon LH challenge. Additionally, boars treated 
with a specific GnRH-I antagonist (SB-75) daily for 96 h displayed suppressed 
testosterone levels for the duration of treatment, whereas LH levels returned to basal after 
only 36 h of treatment (Fig. 1.1; Zanella et al., 2000). Consistent with this, testicular 
explant cultures treated with human chorionic gonadotropin in the presence of SB-75 
produced less testosterone compared to controls (Zanella et al., 2000). Given that 
GnRHR-I has never been detected in the boar testis, Zanella et al. (2000) postulated that a 
different mechanism must be controlling testosterone production directly at the testis. 
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Differential regulation of testosterone secretion could lead to advancements in 
human fertility treatments, contraceptives, cancer research or pharmacological agents. 
Moreover, the discovery of autocrine or paracrine mechanisms for testosterone regulation 
may aid the swine industry as well. If GnRH-II or its receptor are correlated with 
testosterone production, novel screening methods could be utilized in boar studs to 
improve reproductive efficiency. Eliminating infertile or subfertile boars from the herd 
early will reduce the economic losses associated with rearing and training. 
Implementation of these new technologies could lead to enhanced productivity and 
profitability of pork producers.  
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Figure 1.1. The relative change in plasma LH and testosterone concentrations in 
white crossbred (WC) and Chinese Meishan (MS) boars after administration of a 
specific GnRHR-I antagonist, SB-75 (arrows). Levels of LH returned to normal 36 h 
after the initial treatment, whereas testosterone concentrations remained suppressed 
for 96 h. From Zanella et al. (2000). 
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CHAPTER II 
 
LITERATURE REVIEW 
 
Gonadotropin-Releasing Hormone I 
Structure. Gonadotropin-releasing hormone (GnRH) has been conserved 
throughout 500 million years of evolution (Millar, 2005) and has been discovered in 
every vertebrate class examined (Tsai and  Zhang, 2008). For almost 30 years, GnRH 
was thought to be a novel decapeptide (Schally, 1973), however, 23 other forms of GnRH 
have been identified since then (Millar, 2005), all with 10 amino acids and at least a 50% 
sequence identity (Dubois et al., 2002).  In vertebrates, 3 forms are the most common 
(Table 2.1; Millar, 2005). The classical form of GnRH has been designated GnRH-I, as it 
was the first form to be discovered in mammalian hypothalamic tissues (Baba et al., 
1971; Matsuo et al., 1971; Schally et al., 1971). Two isoforms, GnRH-II and GnRH-III, 
were later isolated in the chicken (Miyamoto et al., 1984) and lamprey (Sower et al., 
1993), respectively.  Today, it is well known that these 2 isoforms are also prevalent in 
vertebrates (Millar, 2005).  GnRH-II is present in many mammalian species, but to date 
GnRH-III has not been identified in mammals (White et al., 1998).  
GnRH-I is a polypeptide consisting of 10 amino acids: pGlu-His-Trp-Ser-Tyr-
Gly-Leu-Arg-Pro-Gly-NH2 (Baba et al., 1971; Matsuo et al., 1971; Schally et al., 1971).  
The amino acid in the eighth position is considered to be the most variable (followed by 
5, 6 and 7) among all isoforms of GnRH. However, Arg must be in position 8 for 
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TABLE 2.1. COMPARISON OF GnRH ISOFORMS IN VERTEBRATES. 
Isoforms Amino Acid Sequence
a
 
GnRH-I pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
GnRH-II pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 
GnRH-III pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 
     
a
 Amino acids in bold are different from the classic mammalian decapeptide, GnRH-I. 
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gonadotropin production in the pituitary (Karten and  Rivier, 1986; Sealfon et al., 1997). 
The NH2- and COOH-termini of GnRH-I have been identically conserved through 
evolution, indicating absolute necessity for biological function (Millar, 2005). The 
residues on the NH2-terminus are involved in receptor activation and binding. While the 
COOH-terminus is only involved in receptor binding.  The conformation of GnRH-I is 
considered a β-II type turn involving amino acids 5-8 (Fig. 2.1; Karten and  Rivier, 1986; 
Sealfon et al., 1997).  Substitutions with D-amino acids in the NH2- terminus result in 
antagonist production whereas substitutions at residue 6 (Gly) will enhance binding 
affinity by stabilizing the conformation and therefore, increasing the half-life (Millar, 
2002).  
 
Reproductive Function. GnRH-I may have first functioned in cell to cell 
communication for reproduction in simple invertebrates (Millar, 2005). Indeed, GnRHs 
have been found in the neural tissue of marine filter feeders and they function to activate 
the gonads through release into the bloodstream (Powell et al., 1996).  Interestingly, this 
occurs without an organized pituitary gland, suggesting regulation of reproduction by the 
pituitary, as within mammals, came later in evolution (Millar, 2005).  
Mammalian production of GnRH-I occurs in approximately 1,000 specialized 
neurons originating from the preoptic area and mediobasal hypothalamus of the brain. A 
precursor polypeptide is enzymatically cleaved and packaged in secretory granules which 
are then transported through axons, terminating within the medium eminence (Seeburg et 
al., 1987; Fink, 1988). Newly synthesized GnRH-I is secreted in a pulsatile manner 
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Figure 2.1. Conformation of GnRH-I when bound to the GnRHR-I. The NH2-terminus is 
involved in receptor binding and activation, whereas the COOH-terminus is only needed 
for receptor binding.  D-amino acid substitution of residues in the NH2-terminus will 
result in the production of an antagonist, whereas substitutions for Gly
6
 will produce an 
agonist, marked by increased binding affinity and half-life.  From Millar et al. (2005). 
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(every 30 - 120 min) into the hypothalamic-hypophyseal portal system, for transport to 
the anterior pituitary gland (Fink, 1988). However, clearance of GnRH-I in blood occurs 
quickly, with a half-life of approximately 2 - 8 min (Pimstone et al., 1977).   
Once GnRH-I reaches the anterior pituitary gland, the GnRH-I receptor (GnRHR-
I) is upregulated in gonadotrope cells to aid in ligand binding for signal transduction 
(Lahlou et al., 1987). Next, gonadotropin production and secretion is initiated through the 
transcription and translation of genes encoding the common α-glycoprotein and the 
distinct FSHβ- and LHβ-subunits (Conn and  Crowley, 1991; Stojilkovic and  Catt, 
1995). Heterodimerization of the common α-subunit and specific β-subunits result in the 
glycoprotein hormones, follicle stimulating hormone (FSH) or luteinizing hormone (LH; 
Conn and  Crowley, 1991; Stojilkovic and  Catt, 1995). A pulse of LH occurs after every 
pulse of GnRH-I, however, synthesis and secretion of FSH occurs in a more constitutive 
manner (Millar, 2005). Studies demonstrated that LHβ-subunit production is favored 
when pulses of GnRH-I are frequent (1/min) whereas the FSHβ-subunit is preferentially 
produced when pulses occur every 120 min (Kaiser et al., 1997).  While GnRH-I 
stimulates gonadotropin production, constant GnRH-I stimulation will reduce 
gonadotropin secretion due to GnRHR-I downregulation and desensitization of 
gonadotrope cells (Millar et al., 1987; Casper, 1991; Conn and  Crowley, 1991).   
 
Gonadotropin Releasing Hormone Receptor I 
Structure.  The mouse GnRHR-I was first cloned in the early 1990’s (Tsutsumi 
et al., 1992). Classified as a 7-transmembrane (TM), G-protein coupled receptor (GPCR), 
11 
 
it is a member of the rhodopsin-like GPCR superfamily (Fig. 2.2; Cheng and  Leung, 
2005).  Although it is among the smallest GPCRs ever identified at 327 amino acids 
(Brothers et al., 2002), this receptor has stringent requirements for ligand conformation 
(Millar et al., 1987).  Like most GPCRs, the NH2-terminal domain is followed by 7 
putative, α-helical TM domains connected by 3 extracellular loop (ECL) domains and 3 
intracellular loop (ICL) domains. The ECL are thought to be involved in ligand binding 
and the TM domains are associated with the conformational change needed for receptor 
activation (Millar, 2005).   
Most GPCRs have intracytoplasmic tails which are associated with rapid 
desensitization and internalization (Pawson et al., 2003b).  In the GnRHR-I, the carboxyl 
tail is truncated at the plasma membrane after the seventh TM domain (Eidne et al., 
1992). Millar (2005) hypothesized that the absence of the carboxyl-terminal tail, must be 
due to a recent beneficial adaption.  Although there is no defined tail, the carboxyl-
terminal amino acids of TM 7 are important for G-protein coupling, the intracellular 
mechanism which initiates signal transduction.  Since the last 4 residues are conserved in 
all mammals, they are perceived to be essential to receptor signaling. For example, a 
mutant GnRHR-I (Ser
326
Tyr) decreased G-protein coupling, and the mutation of all 
terminal residues resulted in no effector coupling. The ICL within the GnRHR-I are 
important for G-protein coupling to the receptor.  Both ICL 2 and ICL 3 are thought to 
couple with the G-protein subunit, Gq/11, whereas ICL1 is involved in Gs signaling (Millar 
and  Pawson, 2004).   
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Cell Signaling.  Gonadotropes make up only 5-10% of the cell population within 
the anterior pituitary gland but are widely dispersed (Naor and  Huhtaniemi, 2012).  
Although they are not localized in 1 region of the pituitary, they coordinate together to 
create pulses of gonadotropin secretion (Krsmanovic et al., 1993). In fact, even 
gonadotropes dissociated from adjacent cells in culture will secrete gonadotropins in a 
synchronized fashion (Krsmanovic et al., 1993).  Binding of GnRH-I to its cognate 
receptor is a basic ligand-receptor interaction. Binding stimulates intracellular signaling 
by initiating receptor activation and conformational changes (Wu et al., 2009). Upon 
binding, GDP is exchanged for GTP in heterotrimeric G-protein complexes. This causes 
the dissociation of the subunit Gα from Gβγ, resulting in GTP hydrolysis by GTPase 
activity. Formation of the Gα-GDPβγ complex resumes and the receptor returns to its 
inactive conformation, however signal transduction has begun (De Lean et al., 1980). In 
the pituitary, the predominate G-protein associated with gonadotropin secretion is Gq/11 
(Fig. 2.3; Ando et al., 2001; Ferris et al., 2007; Grafer et al., 2009).  The hydrolysis of 
GTP activates the G-proteins, Gq/G11, thereby increasing the activity of phospholipase C 
(PLC) which hydrolyses phosphoinositide, generating inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG).  Increasing levels of intracellular IP3 bind to receptors on the 
endoplasmic reticulum (ER), resulting in sequestered Ca
2+
 release. Meanwhile, DAG 
increases intracellular Ca
2+
 by opening voltage-gated calcium channels in the plasma 
membrane of the cell and activates protein kinase C (PKC; Stojilkovic and  Catt, 1995).  
PKC mediates mitogen activated protein kinase (MAPK) activation, including 
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Figure 2.3. Diagram of cell signaling pathways activated following GnRH-I binding to 
GnRHR-I. When GnRH-I and its receptor bind, Gs/αβγ is activated; causing the 
dissociation of Gs/α that activates adenylate cyclase (AC). Adenylate cyclase converts 
ATP to cAMP which subsequently activates protein kinase A (PKA) and cAMP response 
element binding protein (CREB). Alternatively, Gq/11α stimulates phospholipase C (PLC) 
which converts phosphoinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3). Calcium is released from extracellular and intracellular 
endoplasmic reticulum (ER) stores by DAG and IP3 stimulation. Increased calcium binds 
calmodulin (CaM) and activated calmodulin kinase (CaMK). Protein kinase C (PKC) is 
stimulated by Ca
2+
 and DAG. Multiple mitogen activated protein kinase (MAPK) 
pathways are activated by PKC including extracellular signal-regulated kinase (ERK), c-
Jun N-terminal kinase (JNK), p38 MAPK, and big MAPK (BMK), resulting in the 
recruitment of transcription factors (i.e., Jun and ELK) that stimulate LH and FSH gene 
expression. Adapted from Naor et al. (2000). 
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extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), p38 
MAPK, and ERK5 (big MAPK; BMK). MAPKs will then translocate to the nucleus to  
phosphorylate transcription factors that support gonadotropin gene expression (Naor 
and  Huhtaniemi, 2012), resulting in the synthesis and secretion of LH and FSH.  
Interestingly, certain gonadotropes are capable of secreting both LH and FSH (bi-
hormonal), whereas others secrete gonadotropins in a mono-hormonal fashion (Childs, 
1983).   
While Gq/11 is the principal G-protein activated, GnRHR-I can also utilize other G-
proteins.  Signaling via Gs has been demonstrated in gonadotropes as well as other tissues 
(Ando et al., 2001; Ferris et al., 2007; Grafer et al., 2009).  Once ligand binding occurs, 
the Gα-subunit will dissociate and activate the enzyme adenylate cyclase (AC), which is 
responsible for the conversion of ATP to cAMP.  As cAMP levels rise in the cell, they 
bind regulatory subunits on protein kinase A (PKA), causing the release of catalytic 
subunits responsible for direct protein activation via phosphorylation or protein synthesis. 
Protein synthesis is stimulated when cAMP response element-binding protein (CREB) 
binds to cAMP response elements (CRE) within the promoter of a gene within the 
nucleus of gonadotropes (Cheng and  Leung, 2001).   
This receptor has also been shown to signal through Gi, although the mechanism 
is still poorly understood. This G-protein acts very differently from both Gs and Gq/11, 
rather than activating signal transduction, Gi acts as an inhibitory modulator of cAMP 
production. Specifically, Gi inhibits the activation of AC, preventing the production of 
cAMP. For example, when rat gonadotropes were treated with pertussis toxin, 
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intracellular IP3 levels were significantly reduced, indicating the activation of the Gi 
subunit (Hawes et al., 1993).  Moreover, it has been demonstrated that GnRHR-I couples 
to Gi in many cancerous tumors including ovarian, uterine (Imai et al., 1996), and 
prostate (Limonta et al., 1999).   
While it is apparent that GnRHR-I can signal through many different G-proteins, 
the mechanism behind G-protein selectivity is unclear.  Interestingly, GnRHR-I appears 
to be in a different conformation for activation of Gi versus Gs and Gq/11. This 
conformational selectivity of GnRHR-I may be due to many factors, including the nature 
of the ligand (Millar, 2005), cell type, cell cycle stage or the mere availability of Gi 
machinery within the cell (Millar et al., 2004). Additionally, GnRHR-I has allosteric sites 
thought to cause alterations in conformation (Millar et al., 2004). In fact, some 
researchers postulated that the conformational selectivity of GnRHR-I in a particular cell-
type or cellular environment can dictate the type of G-protein utilized due to allosteric 
sites alone (Naor and  Huhtaniemi, 2012). Interestingly, GnRHR-I also activated multiple 
signaling cascades through Gq/11 alone in αT3 cells (Grosse et al., 2000).   
 
Internalization. Classically, GPCRs are internalized by GPCR kinases, β-arrestin 
and clathrin-coated pits (Millar et al., 2004). After receptor activation and the generation 
of free Gβγ-subunits, GPCR kinases phosphorylate the receptor at specific serine and 
threonine residues (De Camilli et al., 1995). Phosphorylation enhances the binding of the 
protein, β-arrestin, thought to be the signal for internalization.  Next, the GTPase, 
dynamin, initiates formation of a clathrin-coated pit from an invagination of the plasma 
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membrane (De Camilli et al., 1995). The specialized vesicle surrounds and engulfs the 
receptor, removing it from the plasma membrane.  The clathrin is degraded in the 
cytoplasm of the cell and the vesicle fuses with an endosome (Sorkin and  Von Zastrow, 
2002).  Here, the path of the internalized receptor can vary.  Receptors can either be 
sequestered in endosomes, recycled back to the plasma membrane or transported to 
lysosomes for proteolysis (Sorkin and  Von Zastrow, 2002).  Although GPCRs, like 
GnRHR-I, are most commonly internalized by clathrin-coated pits, they can also be 
internalized by smooth, non-coated membranes, vesicles or caveolae, independent of β-
arrestin or dynamin (Raposo et al., 1989; Anderson, 1998; Claing et al., 2000).  
 
Tissue Expression. Once considered a solely hypothalamic hormone (Schally et 
al., 1971), later evidence suggests GnRH-I is also produced in low levels (White et al., 
1998) elsewhere in the body (Gibbons et al., 1975).  GnRH-I is widely distributed outside 
of the brain (Barry, 1979; Sharpe et al., 1982). However, its size, short half-life and 
relatively low concentration make an extra-pituitary endocrine function infeasible (Nett et 
al., 1974; Pimstone et al., 1977). Thus, many have hypothesized that GnRH-I is produced 
locally (Sharpe and  Cooper, 1982a).  Indeed, studies suggest that extrapituitary GnRH-I 
was produced in an autocrine or paracrine manner (Millar, 2005; Lin et al., 2010).  
Further, Millar (2002) suggested that wide tissue distribution indicates many reproductive 
and non-reproductive functions have yet to be identified for GnRH-I.  To date, GnRH-I 
has been found in the kidney, pancreas, lymph system, adrenal, pancreas, retina, the 
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immune system and extrahypothalamic brain, as well as reproductive tissues like the 
gonad, uterus, placenta, breast and prostate (Cheng and  Leung, 2005; Millar, 2005).   
In situ hybridization revealed GnRH-I mRNA in granulosa cells of primary, 
secondary and tertiary follicles in the rat ovary (Clayton et al., 1992; Whitelaw et al., 
1995).  Further, GnRH-I mRNA was detected in human placental (JEG) cells (Dong et 
al., 1996) and rat gonads (Bahk et al., 1995). In addition, ligand binding sites were 
discovered on granulosa and luteal cells through radioligand binding assays (Clayton et 
al., 1979; Harwood et al., 1980). The localization of GnRH-I and its receptor to the 
gonads and other reproductive tissues of mammals indicates a specific function (Millar, 
2003). Interestingly, GnRH-I is also present in non-mammalian vertebrates suggesting 
the development of an early reproductive function, possibly before the development of 
the hypothalamic-pituitary-gonadal (HPG) axis (Millar, 2005).   
        
GnRH-I and its Receptor in the Testis. Evidence for the presence of a testicular 
GnRHR-I was first discovered in the late 1970s, when LH receptor mRNA levels 
increased in response to GnRH-I administration in hypophysectomized rats (Hsueh 
and  Erickson, 1979).  Since then, GnRHR-I has been detected in the testis of many 
species including the human (Clayton et al., 1980; Bahk et al., 1995), alpaca (Zerani et 
al., 2011), mouse (Bull et al., 2000) frog (Pierantoni et al., 1984; Minucci et al., 1986), 
monkey (Sharpe and  Fraser, 1980) and fish (Pati and  Habibi, 1993). Interestingly, the 
boar (Zanella et al., 2000) and bull (Kakar et al., 1992) lack testicular GnRHR-Is entirely.   
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GnRH-I mRNA has been discovered in adult human testicular tissue, specifically 
in seminiferous tubules, Sertoli cells and some spermatogenic cells. GnRHR-I mRNA 
was also found in germ cells of mice and rats (Bull et al., 2000). Competitive binding 
assays revealed GnRHR-I mRNA within the interstitial compartment of the testis in 
humans and rats, including the Leydig cells (Clayton et al., 1980; Bahk et al., 1995). 
Immunohistochemistry (IHC) and Western blot analyses indicated GnRHR-I was in the 
cytoplasm of alpaca Leydig cells (Zerani et al., 2011). Since Sertoli cells of several 
species can produce GnRH-I (Sharpe and  Fraser, 1980; Verhoeven and  Cailleau, 1985; 
Sharpe and  Cooper, 1987; Saint Pol et al., 1988) and Leydig cells express the GnRHR-I 
(Iwashita and  Catt, 1985; Jegou et al., 1985; Nikula and  Huhtaniemi, 1988; Petersson et 
al., 1989; Reinhart et al., 1992; Kakar et al., 1992), it was hypothesized  that GnRH-I can 
act in a paracrine manner within the testis (Bahk et al., 1995).  
Evidence suggests that GnRH-I has a direct effect on the testis (Lin et al., 2010). 
For example, rats injected with GnRH-I directly into the testis experienced an immediate 
increase in serum testosterone concentration although LH levels were unaffected (Sharpe 
et al., 1983).  Moreover, short term treatment of GnRH-I on rat primary Leydig cell 
cultures increased testosterone production (Sharpe and  Cooper, 1982b; Browning et al., 
1983; Molcho et al., 1984). However, long term exposure to GnRH-I decreased 
testosterone production after human chorionic gonadotropin (hCG) challenge, suggesting 
the downregulation of the GnRHR-I.  Further, administration of GnRH-I to pre-pubertal 
mice increased GnRHR-I mRNA levels in the testes and increased IHC staining for the 
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GnRHR-I in Leydig cells (Anjum et al., 2012).  These effects were also correlated with 
increased expression of the steroidogenic enzyme P450scc.   
Interestingly, the scope of action for GnRH-I in the testis is not limited to 
steroidogenic mediation.  For instance, treatment with a GnRH-I agonist (Buserelin) 
directly increased testosterone production and spermatogonial mitosis in frogs (Pierantoni 
et al., 1984; Minucci et al., 1986), suggesting that GnRH-I might also impact 
spermatogenesis. Subsequent research appears to substantiate these claims as high levels 
of GnRH-I and GnRHR-I mRNA were present in the testes of infertile men (Lin et al., 
2008).  Transcript levels were also correlated with low serum testosterone concentrations 
and testicular volume. Therefore, the authors postulated that increased mRNA transcripts 
for GnRH-I, and GnRHR-I could be indicative of spermatogenic dysfunction, possibly 
due to a compensatory increase in gene transcription (Lin et al., 2008). While testosterone 
is required for proper spermatogenesis, recent research suggests that testosterone can be 
suppressive to proliferation of spermatogonia (Udagawa et al., 2002).  Interestingly, 
treatment with a GnRH-I antagonist (SB-75) reduced intra-testicular testosterone levels 
and increased the regeneration of spermatogenesis by stimulating spermatogonial 
proliferation in irradiated (Shuttlesworth et al., 2000), cryptorchid (Udagawa et al., 
2002), and chemically castrated (Meistrich, 1999) rats, as well as mutant, spermatogonial 
depleted mice (Matsumiya et al., 1999). 
  In addition to the regulation of steroidogenesis and spermatogenesis, there is also 
evidence that supports a role for GnRH-I in fertilization.  For example, ~350-fold more 
human spermatozoa bound the zona pellucida of an oocyte when first exposed to GnRH-I 
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(Morales, 1998), indicating that spermatozoa may interact with GnRH-I as they travel 
through the male and female reproductive tract, increasing the fertilization capacity.  This 
effect was completely blocked by a GnRH-I antagonist (Morales et al., 1999).  Similarly, 
GnRHR-I has been found on mouse spermatozoa, also indicating that the interaction 
between testicular GnRH-I and GnRHR-I may be an important regulator of 
spermatogenesis (Anjum et al., 2012). 
Localized testicular GnRH-I may also be involved in development of puberty and 
reproductive senescence of the male mouse. It is well recognized that puberty is achieved 
when GnRH-I neurons are stimulated to begin secretion and reproductive senescence is 
marked by drastic reductions in testosterone production (Chandolia et al., 1997).  
Interestingly, FSH and LH levels increased at senescence, suggesting a primary testicular 
defect initiates reductions in testosterone (Zwart et al., 1996).  Indeed, Anjum and 
coworkers (2012) discovered that increased staining for the testicular GnRHR-I coincided 
with the onset of puberty in the mouse whereas reproductive senescence coincided with a 
reduction in GnRHR-I staining in the testis, followed by a compensatory increase in 
GnRH-I. The authors proposed that this phenomenon may work synergistically with 
regulation of puberty and senescence at the level of the hypothalamus (Anjum et al., 
2012).  In conclusion, it appears that GnRH-I and its receptor regulate testicular function 
in 2 ways, indirectly through alterations in gonadotropin secretion and directly at the 
level of the testis (Botte et al., 1999).  
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Role in Cancer. Classically, GnRH-I has been used to inhibit androgen 
dependent cancer growth (Engel and  Schally, 2007). Both GnRH-I agonists and 
antagonists are useful treatments as they either downregulate or block the GnRH-I 
receptor in the hypothalamus, reducing androgen levels (Engel and  Schally, 2007).  In 
prostate cancer, androgens are vital mitogenic signals for normal cell proliferation, but 
can also be the cause of an imbalance in cell division (Cook and  Sheridan, 2000).  
Indeed, the instances of prostate cancer in castrated males are rare (Huggins and  Hodges, 
2002).  In early stages of prostate cancer, androgen deprivation is suppressive to cancer 
growth, however, an androgen independent growth stage will develop over time (Navarro 
et al., 2002).   
Interestingly, GnRH-I can also have a direct effect on prostate cancer cell growth 
without working through the HPG axis, and thus, is also a potent androgen independent 
inhibitor of cancer growth (Moretti et al., 1996). For example, the invasiveness of 
prostate cancer cells was reduced when treated with GnRH-I, through activation of Gi 
and inhibition of epidermal growth factor (Moretti et al., 1996). Moreover, insulin-like 
growth factor-induced cell proliferation was mitigated by GnRH-I agonist treatment 
(Zoladex; Moretti et al., 1996; Marelli et al., 1999).  Similarly, in vitro proliferation of 
endometrial, ovarian and breast cancer cells was diminished after treatment with GnRH-I 
agonists (Emons et al., 2003) and antagonists (Emons et al., 1993a; Emons et al., 1993b; 
Irmer et al., 1995; Emons et al., 1997; Grundker et al., 2002b). Interestingly, breast 
cancer cell proliferation was reduced whereas cell apoptosis was increased after treatment 
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with GnRH-I (Hong et al., 2012). Indeed, GnRH-I analogues can inhibit tumor growth in 
both an anti-proliferative and pro-apoptotic manner (Cheung et al., 2006).  
Apoptosis naturally occurs in healthy cells in response to toxic stimuli or 
developmental signals and hallmarks include DNA fragmentation, cell shrinkage, plasma 
membrane blebbing and formation of apoptotic bodies (Jin and  El-Deiry, 2005; Elmore, 
2007). Treatment with GnRH-I induced apoptosis in rat granulosa cells and human 
myometrium cells in vivo and in vitro (Yano et al., 1997; Wang et al., 2002). Similarly, 
pro-apoptotic signals increased in human cancer cell lines (benign prostate hyperplasia 
and choriocarcinoma) treated with GnRH-I via activation of Gi (Maudsley et al., 2004). 
In addition, GnRH-I has apoptotic effects on human granulosa cells (Leung et al., 2003), 
activating the proteolytic caspase-dependent extrinsic signaling cascade rather than the 
intrinsic pathway that involves Bcl-2 members (Hong et al., 2008).  Interestingly, 
treatment of rat granulosa cells with a GnRH-I agonist (leuprolide acetate) involved some 
Bcl-2 members, suggesting the mechanism initiating apoptosis may be species-specific 
(Parborell et al., 2008).  Induction of apoptosis by GnRH-I was also shown in human 
breast cancer cell lines through stress-activated p38 MAPK, loss of mitochondria 
membrane potential and activation of caspase-3 (Grundker et al., 2010).  
 
Gonadotropin-Releasing Hormone II 
Structure.  The second isoform of GnRH, GnRH-II, was originally identified in 
the chicken hypothalamus (Miyamoto et al., 1984).  Since then, it has been found in 
animals of every vertebrate class, from lower orders, such as bony fish, to complex 
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mammals, like humans (Fernald and  White, 1999), suggesting it may be the most ancient 
form of GnRH (Millar et al., 2004).  In these animals, the structure of GnRH-II remains 
entirely conserved, indicating high selection pressure and thus, a critical evolutionary 
function (Millar and  King, 1987).  Therefore, complete conservation has persisted 
despite 500 million years of evolution (Fernald and  White, 1999).  GnRH-II is also a 
decapeptide (Table 2.1), differing from GnRH-I by only 3 amino acids (His
5
,Trp
7
,Tyr
8
; 
Miyamoto et al., 1984), giving it a 70% sequence identity to GnRH-I (White et al., 1998).  
Moreover, GnRH-II has a β-turn conformation similar to GnRH-I.  However, GnRH-II 
exists in a preconfigured conformation, unlike GnRH-I.  Thus, GnRH-II does not require 
extensive conformational changes for receptor activation (Pfleger et al., 2002; Millar, 
2003).  This indicates GnRH-II has increased stability over GnRH-I, approximately 6-
fold higher (Siler-Khodr and  Grayson, 2001),  which may be reflected in its diverse 
tissue distribution (Pawson et al., 2003b).   
 
Tissue Distribution.  Like GnRH-I, GnRH-II is present in the brain, specifically 
the pre-optic and medio-basal hypothalamic areas, the midbrain and limbic structures 
(Sealfon et al., 1997; Millar et al., 2001; Millar, 2002).  However, GnRH-II was only 
scarcely found in the hypothalamic regions known to regulate gonadotropin secretion 
(Rissman et al., 1995).  In primates and humans, GnRH-II has also been isolated in the 
caudate nucleus, hippocampus, amygdala and the peripheral nervous system (Lescheid et 
al., 1997; Urbanski et al., 1999).  Similar to GnRH-I, GnRH-II was also found outside of 
the brain, potentially due to autocrine or paracrine production as determined by gene 
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expression analysis (Cheon et al., 2001; Kang et al., 2001; Millar, 2003). Interestingly, 
GnRH-II is expressed at the highest level outside the brain (White et al., 1998).  GnRH-II 
mRNA has been detected in the kidney, bone marrow, prostate (White et al., 1998), testis 
(An et al., 2008), placenta (Siler-Khodr and  Grayson, 2001), uterine endometrium 
(Cheon et al., 2001), and mammary gland (Chen et al., 2002), as well as ovarian 
epithelial (Choi et al., 2001) and granulosa cells (Kang et al., 2001).  Although GnRH-I is 
also present in many extra-hypothalamic tissues, GnRH-II is considered to be more 
ubiquitously expressed (Millar et al., 2004).  Given the diverse tissue distribution of 
GnRH-II, many have hypothesized different roles for this ligand.   
 
Role in Reproduction.  Since this peptide was first localized to the brain, it was 
originally speculated that GnRH-II functions like GnRH-I in gonadotropin release 
(Rissman et al., 1995).  Indeed, early studies with mammalian pituitary cultures found 
that high doses of GnRH-II could stimulate LH release, albeit at about 2% the efficacy of 
GnRH-I (Millar and  King, 1983; Millar et al., 1986).  Additionally, infusions of GnRH-
II could stimulate ovulation, but with only ~10% the potency of GnRH-I (Rissman et al., 
1995).  Given that GnRH-II was a less efficient stimulator of gonadotropin secretion, it 
was postulated that its action was mediated through a receptor for which it has a low 
affinity (Schneider and  Rissman, 2008).  It is known that GnRH-II has its own specific 
receptor (GnRHR-II) but it can also bind the GnRHR-I with low affinity (Millar, 2003), 
potentially indicating why GnRH-II had a lower potency than GnRH-I in these 
experiments.  This is supported by the results of later experiments on sheep (Gault and 
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Lincoln, 2002), musk shrews (Kauffman et al., 2005) and primates (Densmore 
and  Urbanski, 2003; Okada et al., 2003).  When given a GnRH-I antagonist (SB-75) 
prior to administration of GnRH-II, the modest stimulation of gonadotropin secretion or 
ovulation by GnRH-II was completely attenuated (Densmore and  Urbanski, 2003; Okada 
et al., 2003; Kauffman et al., 2005).  Moreover, primary porcine pituitary cultures 
released LH and FSH in response to GnRH-II, although this effect was mitigated with 
SB-75 pre-treatment (Neill et al., 2002a).  Thus, it is now generally accepted that only 
high doses of GnRH-II can stimulate modest gonadotropin secretion through the 
GnRHR-I (Densmore and  Urbanski, 2003; Okada et al., 2003; Schneider and  Rissman, 
2008).  Therefore, researchers began examining other roles for GnRH-II in mammals.   
Given the distribution of GnRH-II in reproductive tissues, many have examined 
its role in extra-pituitary reproductive function.  Research suggests that GnRH-II may 
have a specific role in ovarian steroidogenesis and implantation/placentation.  For 
example, GnRH-II modulated the action of gonadotropins on the ovary by down-
regulating mRNA for the LH and FSH receptors (Kang et al., 2001).  Moreover, GnRH-II 
was detected in the ovary of the baboon, with exogenous administration reducing 
progesterone production from cultured granulosa cells (Siler-Khodr et al., 2003).  
Additionally, studies have shown that GnRH-II is produced in the human placenta and 
may affect placentation as exogenous administration of GnRH-II to placental explants 
elicited the production of hCG (Siler-Khodr and  Grayson, 2001).  Furthermore, GnRH-II 
was found in the uterine endometrium at all phases of the menstrual cycle with 
expression increasing during the secretory phase, indicative of a role in implantation 
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(Cheon et al., 2001).  Also, invasion of trophoblast cells in the placenta was stimulated by 
GnRH-II (Chou et al., 2002; Chou et al., 2003b).  
There is also evidence that GnRH-II may impact male reproduction, specifically 
steroidogenesis and spermatogenesis in the testis.  For example, testicular GnRH-II 
mRNA levels in the black porgy fish increased at maturity (An et al., 2008).  In African 
catfish, GnRH-II either impaired or had no effect on LH stimulated androgen production 
by the testes (Schulz et al., 1997).  However, GnRH-II treatment (5 µg/kg BW) alone 
raised plasma LH concentrations.  Moreover, boars immunized against GnRH-II had 
reduced serum testosterone production compared to control boars, although LH levels 
remained unchanged (Bowen et al., 2006).  Furthermore, primary Leydig cell cultures 
from GnRH-II immunized and control animals demonstrated that GnRH-II immunized 
boars produced less testosterone in response to LH. Additionally, testicular GnRH-II 
transcripts were increased in azoospermic men, corresponding with elevated intra-
testicular testosterone levels and increased expression of CYP11A1 and HSD3B2 (Lin et 
al., 2008), suggesting the increase in transcripts may be compensatory. Consistent with 
this, GnRH-II transcripts were detected in human sperm by in situ hybridization, 
suggesting a role for GnRH-II in spermatogenesis (van Biljon et al., 2002).  In contrast, a 
study in mice concluded that GnRH-II did not impact spermatogenesis (Khan et al., 
2007). However, mice lack both endogenous GnRH-II and its receptor (Stewart et al., 
2009), therefore, the actions of GnRH-II in this study were likely due to the interaction of 
GnRH-II with the GnRHR-I.  
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Role in Behavior.  Given the neural location of GnRH-II, many early papers 
hypothesized that it may be important in animal behavior (Muske et al., 1994; Rissman et 
al., 1995; King and  Millar, 1995). The first evidence demonstrating a role for GnRH-II 
in female reproductive behavior was in 1997 (Maney et al., 1997).  Investigators found 
that GnRH-II, but not GnRH-I, infusions into the brain increased female sparrow 
receptivity behavior to male song.  Later, the effects of GnRH-II were examined in feed 
restricted and ad libitum fed, female musk shrews.  Feed restricted musk shrews 
displayed fewer sexual behaviors and had reduced GnRH-II mRNA levels in the brain 
(Kauffman et al., 2006).  Moreover, central infusions of GnRH-II restored the sexual 
behavior of feed restricted, but not ad libitum fed, females within minutes.  Conversely, 
GnRH-I only stimulated behaviors in ad libitum fed animals (Temple et al., 2003a).  
Interestingly, GnRH-II mRNA levels were not lowered in feed restricted males and 
sexual behaviors were not altered by feed restriction or GnRH-II administration 
(Kauffman et al., 2006).  This is potentially due to the sexually dimorphic expression 
pattern of GnRH-II in the brain of musk shrews or the level of feed restriction (Schneider 
and  Rissman, 2008).  In a subsequent experiment on female musk shrews, restoration of 
sexual behaviors in feed restricted animals was not altered by use of a GnRHR-I 
antagonist, suggesting the effect was likely mediated by the GnRHR-II (Kauffman et al., 
2005).  This is in agreement with later studies on female marmoset monkeys indicating 
that GnRH-II and a compound that acts as both a GnRH-II agonist and GnRHR-I 
antagonist (135-18) increased proceptive (sexual solicitation) behaviors, regardless of 
nutritional plane (Barnett et al., 2006).  The results of these studies demonstrates that 
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GnRH-II influences female reproductive behavior through the GnRHR-II, not GnRHR-I.  
Moreover, GnRH-II may be acting as a permissive neurotransmitter to reproductive 
behaviors based on nutritional status in some species (Temple et al., 2003b; Kauffman et 
al., 2005).   
 
Role in Nutrition.  Since the stimulatory effect of GnRH-II on reproductive 
behavior was only observed after feed restriction in some species, GnRH-II was 
examined for a role in nutritional balance.  As previously indicated in musk shrews, feed 
restriction reduced reproductive behaviors and GnRH-II mRNA levels within the 
ventromedial nucleus midbrain, midbrain-hindbrain boundary, and periaqueductal gray 
areas of the brain.  After only 90 min of ad libitum feeding post-restriction, sexual 
behaviors and GnRH-II mRNA levels in the ventromedial nucleus midbrain and 
midbrain-hindbrain boundary rebounded, whereas mRNA levels in the periaqueductal 
gray area remained suppressed (Kauffman et al., 2006), suggesting that energy balance 
can regulate both transcription and translation of the GnRH-II gene (Schneider 
and  Rissman, 2008).  In underfed musk shrews, intracerebroventricular infusions of 
GnRH-II reduced feed intake (33%).  Similarly, this was also demonstrated in ad libitum 
fed musk shrews, only to a lesser extent (28%; Kauffman and  Rissman, 2004b).  
Regardless of nutritional plane, altered feed intake was acute, beginning 90 min after 
GnRH-II infusion and persisting for 3 h (Kauffman and Rissman, 2004b).  This effect 
was thought to be mediated solely through the GnRHR-II as inhibition of the GnRHR-I 
with a GnRH-I antagonist did not prevent reductions in feed intake (Kauffman et al., 
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2005).  Therefore, if energy balance is low, GnRH-II production reduces, inhibiting 
reproductive behaviors and increasing feed intake.  In contrast, if energy is abundant, 
increased GnRH-II production will favor mating (Kauffman and  Rissman, 2004a).   
 
Role in Cancer.  It is widely accepted that continuous administration of GnRH-I 
inhibits the proliferation of reproductive tumor cells, typically through Gi activation 
(Grundker et al., 2002a; Grundker and  Emons, 2003; Limonta et al., 2003).  Recent 
evidence suggests that GnRH-II may also function to regulate cell proliferation and 
migration in a variety of reproductive cancers (Grundker and  Emons, 2003).  Indeed, 
GnRH-I and -II mRNA were overexpressed in cancer cells and inhibited ribosomal 
phosphoproteins, which are needed for proper protein translation (Chen et al., 2002).  
Interestingly, administration of exogenous GnRH-II exerted a more potent anti-
proliferative effect on human breast cancer, endometrial and ovarian cells than GnRH-I 
(Grundker et al., 2002a). GnRH-II also more potently mitigates the pro-angiogenic effect 
of vascular endothelial growth factor (VEGF) in human ectopic stromal cells than GnRH-
I, reducing VEGF production in a dose-dependent manner (Huang et al., 2010). 
Moreover, in malignant tissues, endogenous GnRH-II up-regulated matrix 
metalloprotenases (MPP), key regulators of tumor cell invasion (Ling Poon et al., 2011).  
Additionally, treatment with a GnRH-II agonist reduced cell proliferation by inhibiting 
mitogenic signal transduction via activation of phosphotyrosine phosphate (Grundker et 
al., 2001).  Further, treatment with D-Lys
6
 GnRH-II inhibited the mitogenic effects of 
epidermal growth factor (Eicke et al., 2006).  In many cases, these effects were not 
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mediated through the GnRHR-I, suggesting a role for GnRHR-II in humans (Grundker et 
al., 2004a; Maiti et al., 2005; Eicke et al., 2006). 
In addition to anti-proliferative actions, GnRH-II analogues may also exert pro-
apoptotic effects on cancer cells.  Treatment with a GnRH-II antagonist inhibited growth 
of human cancer cell xenotransplants in nude mice, as well as induced apoptosis in 
human endometrial and ovarian cancer cells in vitro by the loss of mitochondrial 
membrane potential and activation of caspase-3 (Fister et al., 2007).  Later studies 
demonstrated that treatment of human granulosa cells with GnRH-II can increase 
TUNEL-positive cells via the caspase-dependent intrinsic pathway alone (Hong et al., 
2012), whereas the apoptotic effects of GnRH-I are mediated through both the caspase-
dependent and Bcl-2 family-dependent intrinsic pathways (Parborell et al., 2008).  
Further, GnRH-II was implicated in initiating apoptosis, disrupting the activity of IGF-1 
signaling by attenuation of Akt phosphorylation (Hong et al., 2012).  In addition to an 
anti-proliferative and pro-apoptotic effect, GnRH-II might also regulate cellular 
degradation.  For example, human prostate cancer cells (PC3) treated with a GnRH-II 
antagonist (Trptorelix-1) displayed increased mitochondrial dysfunction (increased 
reactive oxygen species and decreased membrane potential) as well as autophagosome 
formation (Kim et al., 2009).  Additionally, Western blot analysis of cell lysates revealed 
a decrease in Akt phosphorylation as well as increased c-Jun phosphorylation, additional 
hallmarks of cell autophagy.  In conclusion, these data indicate that GnRH-II may have a 
significant role in cell cycle regulation and GnRH-II analogues could be useful cancer 
therapies in the future. 
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Gonadotropin-Releasing Hormone Receptor II 
 Structure.  Originally cloned in African catfish (Tensen et al., 1997), GnRHR-II 
has recently been discovered in mammals (Neill et al., 2001; Millar et al., 2001).  While 
the gene for the human GnRHR-I is on chromosome 4 (Kakar and  Neill, 1995), an 
additional GnRH receptor-like sequence was found on chromosome 1, showing the 
highest sequence identity (58%) to the fish GnRHR-II. Thus, it was identified as the 
human GnRHR-II gene (Neill, 2002).  The GnRHR-II gene has 3 exons (van Biljon et al., 
2002): exon 1 (920 bp) codes for 4 TM domains, exon 2 (210 bp) contains the sequence 
for TM domain 5 and exon 3 (420 bp) codes for TM domains 6 and 7 (Neill, 2002).  In 
addition, another truncated GnRHR-II gene has also been identified on chromosome 14 
(Neill, 2002), containing only exons 2 and 3 (van Biljon et al., 2002).   
The full-length GnRHR-II is 379 amino acids (Fig. 2.2; Tensen et al., 1997) and 
has only 40% homology to the GnRHR-I (Neill et al., 2001).  In early studies, GnRH-II 
treatment of GnRHR-II transfected cells increased IP3 production, indicating 
functionality through Gqα coupling (Neill et al., 2001).  In contrast, GnRH-I treatment 
elicited ~400-fold less IP3 production, demonstrating that GnRHR-II is highly specific to 
GnRH-II.  Later studies determined that residues in positions 7 and 8 of GnRH-II are 
critical for the selectivity of the GnRHR-II (Wang et al., 2003).  Similar to GnRHR-I, this 
receptor is also a 7-TM, GPCR (Tensen et al., 1997).  However, the GnRHR-II has 
Asp/Asp (N/D) microdomains in TM regions 3 and 7 (Tensen et al., 1997), whereas the 
GnRHR-I has Asn/Asp in TM regions 2 and 7, thought to be important for receptor 
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activation (Flanagan et al., 1999).  Moreover, in the GnRHR-II, the LSD/EP (Leu-Ser-
Asp/Glu-Pro) amino acid sequence of ECL 3, which is important for ligand selectivity of 
the GnRHR-I, is replaced with VPPS (Val-Pro-Pro-Ser).  This indicates the sequence 
VPPS in ECL 3 is important for the selectivity of GnRH-II, as all other known ligand 
binding sites are conserved (Troskie et al., 1998).   
 Unlike GnRHR-I, the GnRHR-II maintains a C-terminal, intracytoplasmic tail 
(Tensen et al., 1997), indicative of differential coupling for signal transduction (Millar, 
2003) and suggesting rapid receptor internalization and desensitization (Heding et al., 
1998; McArdle et al., 2002).  Specifically, GnRHR-II internalization rates were 
dependent on serine residues 338 and 339.  Additionally, the tail may aid in receptor 
expression and regulation given that the addition of the 51 amino acid tail to the rat 
GnRHR-I in transfected cells elevated receptor expression 5-fold and augmented IP 
production (Lin et al., 1998).  The process of internalization also differs between the 2 
receptors, with internalization occurring through clathrin-coated pits, caveolae and β-
arrestin for GnRHR-I, but independent of β-arrestin for GnRHR-II (Pawson et al., 
2003a).   
 
 Species Distribution.  Since the discovery of the GnRHR-II gene in fish (Tensen 
et al., 1997), the sequence has been cloned in other non-mammalian vertebrates like birds 
(Shimizu and  Bedecarrats, 2006), amphibians (Troskie et al., 1997) and reptiles (Troskie 
et al., 1998).  The GnRHR-II gene has also been found in mammals including the human 
(White et al., 1998), pig, cow, chimpanzee (Morgan et al., 2003), sheep (Gault et al., 
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2004b), shrew, African elephant, horse, dolphin, rabbit, guinea pig, squirrel, dog and cat 
(Stewart et al., 2009), as well as old world monkeys such as the rhesus, marmoset, 
African green and macaque (Millar et al., 2001; Neill et al., 2001).  In contrast, the 
GnRHR-II gene is not present in the genome of the mouse and only a fragment of exon 1 
remains in the rat (Stewart et al., 2009).  While the gene is present in many species, some 
species are unable to produce a functional receptor due to coding errors.   
In humans and chimpanzees, the GnRHR-II gene contains a frameshift mutation 
at codon 10 in exon 1, as well as a premature stop codon in exon 2, which would result in 
the production of a receptor fragment (Morgan et al., 2003).  Although this gene is 
transcriptionally active, (Pawson et al., 2003), its functionality is controversial (Neill, 
2002; Millar et al., 2004).  The fragmented protein has been termed the ‘GnRHR-II 
reliquum,’ spanning the cytoplasmic end of the 5-TM domain to the carboxyl-terminus of 
the full-length receptor (Pawson et al., 2005).  Interestingly, the sequence of the GnRHR-
II reliquum is 80% homologous to the full-length, marmoset GnRHR-II sequence, 
suggesting it may maintain functionality (Millar et al., 1999).  Indeed, there has recently 
been strong evidence for the functionality of this receptor in humans (Neill et al., 2004).  
For example, the GnRHR-II reliquum inhibited production of the GnRHR-I at the level of 
the nucleus and golgi apparatus (Pawson et al., 2005).  Further, in human cancer cells 
with reduced GnRHR-I numbers as a result of gene knock-down procedures, GnRH-II 
retains the ability to inhibit cell proliferation (Grundker et al., 2002a; Grundker et al., 
2004b).  Moreover, a GnRH-II receptor-like antigen has been found in human placenta 
and cancer cell lines (Eicke et al., 2005).  Further, GnRH-I and -II have differing effects 
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in human decidual stromal cell primary cultures, with GnRH-I increasing and GnRH-II 
decreasing mRNA and protein expression levels of PAI-1. Like other studies, use of a 
GnRH-I antagonist mitigated the effects of GnRH-I, but not GnRH-II (Chou et al., 
2003a). 
Given the previous evidence, many hypotheses have arisen for how the GnRHR-II 
may retain functionality including: 1) counteractive shifts in the reading frame, 2) 
recoding of stop codons, 3) alternative splicing, 4) alternative protein translation or 5) 
function via association with the GnRHR-I (Neill et al., 2004).  First, a corrective shift in 
the reading frame, albeit rare, has been demonstrated in mammals and allows for the 
production of a full-length protein (Namy et al., 2004).  The use of an alternative start 
codon has also been considered, given a similar phenomenon occurs in the translation of 
the African green monkey GnRHR-II (Neill et al., 2001).  Further, a readthrough of the 
premature stop codon, translating selenocysteine or another amino acid, could allow for 
the translation of a functional human GnRHR-II (Morgan et al., 2003; Millar, 2003; Neill 
et al., 2004) and has been shown in eukaryotes (Robinson and  Cooley, 1997; Bertram et 
al., 2001; Namy et al., 2004).  Moreover, alternative splicing in the pig (Neill et al., 
2002a) and human (Neill, 2002) produces a 5-TM receptor since the reading frame 
disruption near the N-terminus is spliced out (Neill et al., 2004).  The premature stop 
codon, however, is still present in the 5-TM transcript, but readthroughs of stop codons 
are relatively common (Namy et al., 2004). Thus a 5-TM protein may still be translated 
(Neill et al., 2004) and functional (Ling et al., 1999a).  Additionally, fragments of both 
the 5- and 7-TM isoforms may reassociate after translation to form a functional protein 
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(Neill et al., 2004).  This indeed has been demonstrated with other GPCRs, (Schoneberg 
et al., 1995; Gudermann et al., 1997).  Finally, GnRHR-II fragments from either isoform 
may interact with the GnRHR-I to produce a functional receptor within humans (Neill et 
al., 2004).  This hypothesis is supported by the work of Pawson and coworkers (2005), 
finding that GnRHR-II appears to inhibit protein expression of the GnRHR-I.   
Like the human, other species also have disruptions in translation of the GnRHR-
II gene (Fig. 2.4).  The bovine GnRHR-II gene is non-functional due to frameshift 
mutations in all 3 exons, in addition to premature stop codons in exons 2 and 3 (Morgan 
et al., 2006).  In sheep, the GnRHR-II gene contains a premature stop codon in exon 1 
and a 51-bp deletion in exon 2, preventing the translation of a full-length protein (Gault et 
al., 2004b).  Other gene deletions or mutations disrupt the GnRHR-II gene in the 
elephant, squirrel, guinea pig, rabbit, horse, cat, dog and dolphin, preventing the 
production of a functional receptor (Stewart et al., 2009).  In contrast, genes without 
coding errors were found in the orangutan, African green monkey, macaque, marmoset, 
shrew, kangaroo rat, elephant (Morgan et al., 2003) and pig (Neill et al., 2002a; Neill et 
al., 2002b; Morgan et al., 2003).  Interestingly, the only 4 species known to produce both 
GnRH-II and the GnRHR-II are the macaque, marmoset, shrew and pig (Morgan et al., 
2003; Millar, 2005).  Thus, the pig is an excellent model to study the interaction between 
GnRH-II and its receptor.   
Using cDNA from porcine pituitaries, the pig GnRHR-II was cloned and 
sequenced, showing 90% homology with the monkey GnRHR-II (Neill et al., 2002a; 
Neill et al., 2004).  Like other species, the porcine GnRHR-II is a 7-TM GPCR with 379 
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Figure 2.4. Diagram of coding exons for GnRHR-II in the human, sheep, cow, pig 
and rat. Premature stop codons (black boxes) and frame shift mutations (arrows) 
prevent translation of a full-length receptor in the human, sheep and cow. The rat 
only maintains a remnant of exon 1. In the pig, 3 exons code for a 7-TM receptor and 
a 5-TM isoform can be formed by alternative splicing in exon 1. Adapted from 
Brauer (2009) 
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amino acids, a glycosylated N-terminal extracellular sequence, and a C-terminal, 
intracellular tail (Neill et al., 2002a).  This receptor was found to be functional as GnRH-
II stimulation of COS cells overexpressing the GnRHR-II resulted in IP3 production with 
an EC
50
 of 0.5 nM compared to 220 nM for GnRH-I (Neill et al., 2002b).  Interestingly, 
another porcine sequence had 91% homology with a segment of exon 2 in the monkey 
GnRHR-II (Neill et al., 2002a).  Indeed, a 5-TM receptor was also found in porcine 
pituitaries, derived from alternative splicing of the 7-TM receptor (Fig. 2.5; Neill et al., 
2002b).  Specifically, alternative splicing occurs in exon 1, therefore TM domains 1 and 
2 are absent and the extracellular N-terminus couples directly to TM domain 3 (Neill et 
al., 2004).  Interestingly, a 5-TM GnRHR-II has also been described in humans (Neill, 
2002).  While its functionality has yet to be determined, there is precedent for functional 
5-TM, GPCRs (Ling et al., 1999b; Perron et al., 2005; Bokaei et al., 2006; Sanchez et al., 
2012). 
 
Ligand Interaction. Interestingly, GnRH-II can also bind to the GnRHR-I, 
resulting in ~10% the activity of GnRH-I (Neill, 2002). While GnRH-I can also activate 
the GnRHR-II, it binds with 100-fold less affinity than GnRH-II (Table 2.2(Millar, 2003). 
Therefore, it has been postulated that the actions of GnRH-II may have been 
inappropriately ascribed to GnRH-I in previous studies (Neill et al., 2004). Moreover, 
early evidence on the function of GnRH-II may have been misleading, given the issue of 
receptor binding was not addressed (Neill et al., 2004). For example, administration of 
GnRH-II potently induced gonadotropin secretion in primates (Lescheid et al., 1997). 
39 
 
F
ig
u
re
 2
.5
. 
G
ra
p
h
ic
al
 d
ep
ic
ti
o
n
 o
f 
th
e 
p
o
rc
in
e 
5
- 
an
d
 7
-t
ra
n
sm
em
b
ra
n
e 
(T
M
) 
G
n
R
H
-I
I 
re
ce
p
to
r 
is
o
fo
rm
s.
 F
ro
m
 N
ei
ll
 e
t 
al
. 
(2
0
0
4
).
 
40 
 
 
 
 
 
 
 
 
TABLE 2.2. COMPARISON OF RELATIVE BINDING AFFINITIES AND SIGNALING 
MOLECULES BETWEEN THE MARMOSET GnRHR-II AND HUMAN GnRHR-I
a
. 
Binding and Coupling  
Marmoset 
GnRHR-II 
Human 
GnRHR-I 
Binding  
  
GnRH-I  0.02 1.00 
GnRH-II  1.00 0.1 
GnRH III  0.1 0.1 
Coupling  
Gq/11  + + 
Ca2+  + + 
PKC  + + 
ERK1/2  + (protracted) + (transient) 
p38  + nil 
JNK  nil nil 
c-Src  nil + 
Receptor internalization  Rapid slow 
Rapid desensitization  + nil 
a
 Adapted from Millar (2003). 
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However, recent evidence indicates that GnRH-II elicits increases in gonadotropin 
production through the GnRHR-I in vivo (Neill, 2002) and in vitro (Okada et al., 2003). 
Further, the effects of GnRH-I and -II were mitigated with the use of a GnRH-I 
antagonist (SB-75) in human ovarian cancer cells overexpressing the GnRHR-I (Kim et 
al., 2006a). Additionally, it has been suggested that the presence of GnRH-II, but not a 
functional GnRHR-II, in many species may indicate that the GnRHR-I has adopted a 
mediary role for the actions of GnRH-II through alternative active conformations and 
signal transduction pathways (Millar et al., 2004). 
 
Cell Signaling. Like GnRHR-I, GnRHR-II couples to Gq/11 to initiate calcium 
influx and the activation of PKC (Table 2.2; Kang et al., 2000; Millar, 2003; Liu et al., 
2009). Interestingly, GnRHR-II mobilizes intracellular calcium stores without stimulating 
IP3 activity; instead, it activates the ryanodine receptor (Maiti et al., 2005). After 
activation of PKC, GnRH-I and -II differentially stimulate MAPKs (Millar et al., 2001). 
In COS-7 cells overexpressing GnRHR-II, GnRH-I transiently activates ERK1/2 and c-
Src, whereas GnRH-II activates ERK1/2 in a prolonged manner as well as p38 MAPK 
(Millar et al., 2001; Millar, 2003). This was also demonstrated in OVCAR-3 cells, where 
ERK1/2 and p38 MAPK facilitated the effects of GnRH-II (Kim et al., 2004; Kim et al., 
2006b). In human cancer cells, GnRH-II-induced antiproliferative effects were also 
linked to signaling through ERK1/2 (Kim et al., 2005). In fact, use of PD98059, an 
inhibitor of the ERK1/2 pathway, reversed GnRH-II activation of ERK1/2. However, 
neither GnRH-I or -II activates JNK in COS-7 cells overexpressing GnRHR-II (Millar et 
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al., 2001) or OVCAR-3 cells (Kim et al., 2005). Interestingly, the GnRHR-I can initiate 
different cell signaling pathways based on the analogue, dose, duration of treatment and 
cell type (Millar et al., 2004). This also appears to be true for the GnRHR-II as GnRH-II 
altered MMP expression via JNK rather than ERK1/2 in human cytotrophoblasts (Liu et 
al., 2009).  Moreover, GnRH-II stimulated cell proliferation, migration and remodeling in 
a prostate cancer cell line (TSU-Pr1) but was inhibitory to another (DU-145), suggesting 
differential signal transduction in alternate cell types (Enomoto et al., 2006). This was 
also evident in 2 ovarian cancer cell lines, where GnRH-II increased invasion of 
OVCAR-3 but not SKOV-3 cells (Chen et al., 2007).  
 
Tissue Expression. Similar to GnRH-II, GnRHR-II is widely expressed 
throughout the body (Fig. 2.6; Millar et al., 2001). In fact, GnRHR-II mRNA was found 
in every human tissue tested including brain, pituitary, heart, stomach, intestine, kidney, 
spleen, skeletal muscle, thymus, lung, liver, pancreas, adrenal, thyroid, placenta, uterus, 
ovary, breast, prostate and testis (Neill et al., 2001). Additionally, studies utilizing 
marmoset tissues demonstrated that GnRHR-II mRNA is also present in seminal vesicles, 
the epididymis and bladder, as well as the hypothalamus and many other areas of the 
brain (Millar et al., 2001).  Relative to GnRHR-II mRNA amounts in the pituitary, 
expression levels were lowest in the bladder and highest in the testis.  Interestingly, 
testicular GnRHR-II transcripts were increased in infertile men (Lin et al., 2008) and 
were also found in human sperm and post-meiotic germ cells (van Biljon et al., 2002). 
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GnRHR-II mRNA has also been detected in many human reproductive cancer cells, such 
as ovarian (Grundker et al., 2004a), endometrial (Eicke et al., 2006), breast (Chen et al., 
2002) and prostate (Kim et al., 2009). Therefore, like its ligand, GnRHR-II appears to be 
ubiquitously expressed (Millar et al., 2001).  
 
GnRH-II and its Receptor in Boars. Recent evidence suggests that GnRH-II 
and its receptor may have a direct role in regulating testicular function in boars. For 
example, boars immunized against cGnRH-II displayed reduced levels of testosterone 
compared to control boars (Fig. 2.7; Bowen et al., 2006). Interestingly, LH production in 
cGnRH-II immunized animals was not different from control boars (Fig. 2.8). Since 
testosterone is classically regulated by alteration in LH pulses, these results indicate 
immunization against cGnRH-II impacts testosterone directly at the testis, bypassing the 
HPG axis. Consistent with this, primary Leydig cell cultures from GnRH-II immunized 
boars produced less testosterone after LH challenge than cultures from control boars (Fig. 
2.9).  In an experiment, boars treated with a GnRH-I antagonist (SB-75; 10 µg/kg BW) 
daily for 4 d demonstrated suppressed testosterone production throughout treatment, 
whereas LH levels returned to basal 36 h after the initial treatment (Fig. 1.1). Moreover, 
testicular explant cultures challenged with hCG in the presence of SB-75 (250 ng/ml) 
produced less testosterone compared to cultures treated with hCG alone (Fig. 2.10). 
These results indicate that LH is not the sole regulator of testosterone production in the 
boar. Since the GnRHR-I could not be detected in the boar testis (Zanella et al., 2000), it 
has been postulated that a different mechanism may be responsible for localized 
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Figure 2.7. Plasma testosterone levels in barrows, boars or boars immunized against 
cGnRH-II or lGnRH-III. Arrows indicate when the booster (B) immunization was 
administered. Prior to the booster immunization shown (6 wk), animals were also 
given primary (0 wk) and booster (3 wk) immunizations. From Bowen et al. (2006). 
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Time (wk) 
2 3 10 9 8 7 6 5 4 11 12 13 1 14 
Figure 2.8.  Plasma levels of FSH (Panel A) or LH (Panel B) in barrows, boars or 
boars immunized against cGnRH-II or lGnRH-III. Arrows indicate when either the 
primary (P) or booster (B) immunizations were administered. From Bowen et al. 
(2006). 
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Figure 2.9.  The effect of increasing LH levels on testosterone concentrations of 
primary Leydig cell cultures from control boars or boars immunized against cGnRH-
II or lGnRH-III. 
a-d 
Bars without common letters differ significantly (P < 0.05). From 
Bowen et al. (2006). 
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Figure 2.10. The effect of increasing hCG levels, in the presence or absence of SB-
75, on testosterone production from testicular explant media following 3 h of culture. 
Inclusion of SB-75 reduced levels of testosterone compared to the control (P < 0.01). 
From Zanella et al. (2000). 
49 
 
testosterone production. Interestingly, SB-75 can bind the GnRHR-II at high doses, albeit 
with less potency (Maiti et al., 2003).  Given the presence of testicular GnRHR-II mRNA 
in many species (Millar et al., 2001; Neill et al., 2001; van Biljon et al., 2002; An et al., 
2008), it is plausible that GnRH-II and its receptor may directly regulate testosterone 
production in the boar.  
 
Reproductive Physiology of the Boar 
Testosterone Production. The pig is unique among livestock species with the 
largest interstitial compartment and highest abundance of Leydig cells within the testis, 
suggesting a high capacity for steroid production (Fig. 2.11; Fawcett et al., 1973). Indeed, 
numerous steroids have been detected in venous testicular blood of boars (Table 2.3). 
However, the most prominent steroid hormone produced in the testis of boars is of course 
testosterone (Raeside et al., 2006). Testosterone is produced by the Leydig cells in direct 
response to LH stimulation (Odell et al., 1974).  Briefly, LH secreted from the anterior 
pituitary gland travels through the blood to bind and activate LH receptors on Leydig 
cells (Senger, 2012). LH receptors are membrane-bound, GPCRs that function through 
the G-protein, Gs. Activation causes a conformational change, stimulating a cascade of 
intracellular events including: 1) activation of AC, catalyzing the conversion of ATP to 
cAMP; 2) activation of regulatory subunits for protein kinases, causing the dissociation 
of the catalytic subunits; and 3) induction of  intracellular cholesterol availability, 
transcription of genes needed for steroidogenesis and phosphorylation of proteins already 
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Figure 2.11. Photomicrograph of Leydig cells within the interstitium of the boar testis. 
Numerous blood vessels are present but little connective tissue or lymphatics. From 
Fawcett et al. (1973).  
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TABLE 2.3. STEROIDS IN BOAR TESTICULAR VEIN BLOOD
a
. 
C
19
  
 Testosterone 
 Androstenedione 
 Dehydroepiandrosterone 
 Dehydroepiandrosterone sulfate 
 Epiandrosterone sulphate 
 5-Androstene-3β, 17β-diol sulphate 
 5α-Androstene-3β, 17β-diol sulphate 
 11β-Hydroxytestosterone 
 11β-Hydroxyandrostenedione 
 19-Hydroxytestosterone 
 19- Hydroxyandrostenedione 
 5α-Androst-16-en-3α-ol sulphate 
 5α-Androst-16-en-3β-ol sulphate 
 5α-Androst-16-en-3-one 
 5,16-Androstadien-3β-ol sulphate 
C
18
  
 19-Nortestosterone 
 Oestradiol-17β sulphate 
 Oestrone sulphate 
  
a  
Adapted from Raeside et al. (2006).
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present in the cell by protein kinases. The resulting products include steroid-acute 
regulatory protein (StAR), which delivers cholesterol to the mitochondria, as well as 
steroidogenic enzymes (Hunzicker-Dunn and  Birnbaumer, 1985).  
The initial step in steroidogenesis occurs in the mitochondria where the side-chain 
of cholesterol is cleaved by P450 side-chain cleavage (P450scc or CYP11A1) enzyme, 
resulting in pregnenolone. Steroidogenesis can then proceed through 1 of 2 metabolic 
pathways, Δ4 or Δ5 (Fig. 2.12). The pathway utilized is determined based on enzymatic 
competition between 17α-hydroxylase (P450c17; CYP17A1) and 3β-hydroxysteroid 
dehydrogenase (3β-HSD) for pregnenolone, as well as availability of Δ4/Δ5 
intermediates and the relative substrate (Conley and  Bird, 1997).  Interestingly, humans, 
primates, sheep and cattle can only utilize the Δ5 pathway, whereas mice, rats and pigs 
can utilize either the Δ4 or Δ5 pathway (Conley and  Bird, 1997). For example, in COS-1 
cells expressing porcine P450c17, active intermediates of both Δ4 and Δ5 were present 
(Conley, 1992).  In the boar, testosterone metabolism proceeds via the Δ5 route of 
steroidogenesis (Gower, 1972). Therefore, pregnenolone is oxidized to 17α-
hydroxypregnenolone (17OH-P5) by P450C17 (CYP17A1) and then further cleaved to 
dehydroepiandrosterone (DHEA). DHEA is dehydrogenated via 3β-HSD for conversion 
into androstenedione. Finally, androstenedione is converted into testosterone by 17β-
hydroxysteroid dehydrogenase (17β-HSD; Brooks and  Pearson, 1986; Cooke, 1991).  
 
Spermatogenesis. Within the seminiferous tubules are Sertoli cells, joined 
together by tight, occluding and gap junctions (Osman and  Plöen, 1978). In the boar, 
53 
 
A
4
 
T 
Cholesterol 
P
5
 
DHEA 
17OH-P
5
 
Δ4 Pathway Δ5 Pathway 
P450scc 
CYP17A1 
CYP17A1 CYP17A1 
3β-HSD 
3β-HSD 
17β-HSD 
CYP17A1 
P
4
 
17OH-P
4
 
Figure 2.12. The Δ4 and Δ5 pathways of testosterone production. Enzymes: P450 
side-chain cleavage (P450
scc
), Cytochrome P450 17α-hydroxylase (CYP17A1), 3β-
hydroxysteroid dehydrogenase (3β-HSD) 17β-hydroxysteroid dehydrogenase (17β-
HSD). Products: Pregnenolone (P
5
), Progesterone (P
4
), 17α-hydroxyprogesterone 
(17OH-P
4
), 17α-hydroxypregnenolone (17OH-P
5
), dehydroepiandrosterone (DHEA), 
androstenedione (A
4
) and testosterone (T). Adapted from Conley and Bird (1997). 
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Sertoli cells comprise ~25% of the volume density of each tubule (Franca et al., 2005). 
Generally in mammals, the lower the proportion of Sertoli cells within the seminiferous 
epithelium, the greater the Sertoli cell efficiency and therefore, the higher the daily sperm 
production (Russell and  de Franca, 1995). Sertoli cells encase developing germ cells and 
aid in spermatogenesis by providing a variety of functions including: 1) protection by 
compartmentalization, 2) secretion of fluids, proteins and growth factors, 3) phagocytosis 
of degenerating germ cells and excess cytoplasm from developing germ cells, and 4) 
coordinated release of spermatozoa into the lumen of seminiferous tubules (Franca et al., 
2005).  Additionally, hormones produced by both Sertoli and Leydig cells help regulate 
the spermatogenic process, such as testosterone, FSH, estrogen and inhibin (Franca et al., 
2005). Similar to all mammals, the spermatogenic process in pigs is comprised of 3 
phases: spermatogonial (proliferation), spermatocytary (meiosis) and spermiogenic 
(differentiation; Fig. 2.13; Pelliniemi, 1975; Eddy, 2002). Each phase lasts approximately 
2 wk, therefore, the total duration of spermatogenesis is about 40 d in the boar (Franca 
and  Cardoso, 1998). 
 As with other mammals, germ cells in the boar are arranged in segmental stages, 
or 1 stage per tubular cross-section (Franca et al., 2005). Boars have 4 types of 
spermatogonia: undifferentiated type A, differentiated type A, intermediate and type B 
(Frankenhuis et al., 1982), with type B spermatogonia displaying the largest amount of 
visible chromatin (Frankenhuis et al., 1982). In boars, like rodents, the undifferentiated 
type A spermatogonia can be further subdivided into 3 categories based on their 
topographical arrangement: single (As), paired (Apr) and aligned (Aal; Frankenhuis et al., 
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1982). Moreover, As spermatogonia are thought to be true spermatogonial stem cells 
(Frankenhuis et al., 1982). In the beginning of each spermatogenic cycle, spermatogonial 
stem cells (2n) divide into the different types of spermatogonia (mitosis). The number of 
divisions is species-specific and in the boar there are 6 spermatogonial generations (A1-
A4, I, B; de Rooij and  Russell, 2000). Several substances influence spermatogonial 
proliferation, differentiation and apoptosis, such as glial cell line-derived neurotrophic 
factor, stem cell factor, retinoic acids, p53, Bax, and Bcl-xL (de Rooij and  Russell, 
2000).  Moreover, significant germ cell loss (atresia) takes place during this phase in the 
pig, such that only 2-3 spermatozoa out of a possible 10 are produced from each 
differentiated type A spermatogonia. However, this loss is thought to ensure an optimal 
germ cell to Sertoli cell ratio during proliferation (de Rooij and  Russell, 2000). 
Throughout the cycle, cells of the same type undergo synchronous division in the same 
areas of the seminiferous tubule (Berndtson, 1977). Although the cause of this synchrony 
is unknown, the cytoplasmic bridges joining germ cells in the same stage of development 
are potentially involved (Fawcett et al., 1959).   
The spermatocyte stage (meiosis) is characterized by the start of meiotic divisions 
of type B spermatogonia (Frankenhuis et al., 1982). Apoptosis is common during 
meiosis, with losses up to 15% in the boar, likely due to chromosomal defects (Franca 
and  Cardoso, 1998). The division from a primary to secondary spermatocyte ensues next, 
forming a haploid, round spermatid. At this stage, Sertoli cells are still supporting the 
spermatids. In fact, in the boar, each Sertoli cell can support 12-30 spermatids at a time 
(Franca et al., 2005). Haploid, round spermatids now undergo differentiation, which 
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includes 4 steps: the golgi, cap, acrosomal and maturation phases (Berndtson, 1977; 
Senger, 2012). During these phases, nuclear and cytoplasmic structures undergo intricate 
morphological, biochemical and physiological modifications, indicating that elongation 
of the haploid spermatid is governed by transcriptional and translational mechanisms 
(Steger, 1999). Once differentiated, the spermatozoa are released from the Sertoli cells 
(spermiation) which is potentially mediated through cross-talk between cell types (Osman 
and  Plöen, 1978) as well as testosterone and growth factors (Parvinen and  Ventela, 
1999). 
 
Differences Between Chinese Meishan and White Crossbred Boars. Chinese 
Meishan (MS) pigs were imported into the United States in 1989 for reproduction 
research as they are a highly prolific breed, averaging 3-5 more pigs per litter than the 
conventional, white crossbred (WC) pigs typically utilized in industry (Haley et al., 
1995). In addition, MS boars reach puberty at about 56-84 d of age, considerably earlier 
than WC males (120-180 d). In addition, testicular weight is significantly lower in MS 
(30-60 g) versus WC (160-240 g) animals at puberty. At maturity, MS maintain a lighter 
body weight and smaller testicular mass, about half the size of WC. Furthermore, mature 
MS boars produce approximately half the number of spermatozoa per ejaculate compared 
to WC males (Borg et al., 1993). Interestingly, the sperm production per gram of 
testicular tissue does not differ between MS and WC boars (Okwun et al., 1996b). This is 
due to differences in the testis composition of MS animals.  Within the testis, MS boars 
have fewer Sertoli cells; however, each Sertoli cell produces twice as many spermatozoa 
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compared to WC animals (Okwun et al., 1996a). Meishan boars also have fewer Leydig 
cells than WC, although their size is dramatically larger, 2,855 ± 124 µm
3 
compared to 
960 ± 49 µm
3
, respectively
 
(Lunstra et al., 1997). 
 In addition to physiological differences, MS males also have altered endocrine 
profiles at maturity. Compared to conventional breeds, MS pigs have higher overall 
gonadotropin and androgen levels (Lunstra et al., 1997). For example, MS boars have 8-
fold higher FSH levels compared to Duroc animals (Borg et al., 1993).  Like WC pigs, 
gonadotropins increase in response to GnRH-I treatment, however, levels were sustained 
longer in MS than WC boars, suggesting an expanded secretory phase following GnRH-I 
treatment or slower clearance from the body (Wise et al., 1996). In the same study, 
testosterone levels were higher in MS compared to WC boars, but post-castration 
testosterone levels decreased similarly.  Moreover, the administration of testosterone 
propionate or estradiol cypionate caused a similar rate of reduction in gonadotropin 
secretion for both breeds; however, the hormone levels of MS pigs rebounded from 
suppression earlier than WC boars (Wise et al., 1996). This indicates that the HPG axis in 
the Meishan boar functions normally, only with higher overall hormone levels (Lunstra et 
al., 1997), thought to be due to differential pituitary function (Wise et al., 1996). 
 
Specific Antagonists of GnRH Isoforms 
SB-75. Cetrorelix or SB-75 is a highly specific GnRH-I antagonist (Bokser et al., 
1990). Indeed, SB-75 has been shown to have ~ 20-fold greater affinity for the GnRHR-I 
than GnRH-I in a mouse fibroma cell line transfected with GnRHR-I (Beckers et al., 
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1995). The 4 amino acid substitutions in this highly modified decapeptide are credited 
with enhancing its binding affinity for GnRHR-I and thus, its function (Bokser et al., 
1990). In general, antagonists function through competition with endogenous hormones, 
occupying receptors to prevent the binding and action of the native hormone (Millar, 
2005). Receptor binding assays revealed that SB-75 reduced GnRHR-I numbers via 
desensitization and down-regulation (Halmos et al., 1996).  In rats, 100 µg of SB-75 
caused receptor down-regulation in 2 h, reaching a maximal reduction at 6 h (Halmos 
and  Schally, 2002). When SB-75 was given prior to GnRH-I agonist administration, 
production of LH was depressed or even ablated, primarily due to minimal available 
binding sites in the pituitary for GnRH-I (Pinski et al., 1992).  
Through both occupancy and down-regulation, SB-75 has a vast effect on LH and 
subsequent testosterone secretion. Indeed, a single infusion of SB-75 (10 µg/kg BW) to 
castrated rats reduced LH concentrations 80% by 4 h, with levels rebounding after 24 h.  
Higher doses were found to further extend suppression (Bokser et al., 1991). In monkeys 
treated with various doses of SB-75, the serum LH concentration nadir was achieved at 
12 h post-injection and persisted for 96 h (Weinbauer and  Nieschlag, 1993). Daily 
treatment with SB-75 (400 µg/kg BW) for 14 d suppressed testosterone production to a 
level similar to castration (Weinbauer and  Nieschlag, 1993). Moreover, extended daily 
suppression (7 wk) of intact male monkeys resulted in constant suppression of both LH 
and testosterone. As a result, testicular volume was reduced and animals became 
azoospermic, although animals regained normal fertility after cessation of treatment 
(Weinbauer et al., 1994).  
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SB-75 has also been examined in human trials. Healthy males given a single 
subcutaneous injection of SB-75 (1, 2 or 5 mg) displayed maximal testosterone 
suppression after 8-12 h (73, 80 and 91% reduction, respectively). Serum testosterone 
concentrations returned to basal after 24 h in the 1 and 2 mg treatment groups, whereas 
testosterone levels did not rebound until 48 h following treatment with 5 mg of SB-75 
(Behre et al., 1992).  Multiple doses of SB-75 (0.25 - 10 mg) were also given to healthy 
males over 7, 8 or 14 d. Suppression of testosterone was achieved for all treatment levels, 
however, only the highest dose (10 mg) maintained testosterone reduction for the 
duration of the experiment. Lower doses allowed testosterone to rebound after only 2-4 d 
of treatment, despite continued SB-75 administration (Behre et al., 1994). In subsequent 
studies, investigators determined that an elevated initial dose (10 mg) followed by 
maintenance treatments (1 mg) suppressed testosterone secretion throughout treatment 
(Behre et al., 1997).  In conclusion, SB-75 is a potent GnRH-I antagonist that can 
sufficiently suppress LH release and subsequent testosterone synthesis in a dose- and 
time-dependent manner.  
 
Trptorelix-1. A specific GnRH-II antagonist [Ac-D
2
Nal - (4 Cl) D-Phe-D-
2
Pal-
Ser-Tyr-D-Cit-Trp-Tyr-Pro-D-AlaNH
3
], called Trptorelix-1 (Trp-1), has recently been 
developed (Seong and  Cheon, 2007).  It was designed based on the structure of SB-75 by 
substituting amino acids 7 (Trp for Leu) and 8 (Tyr for Arg; Seong and  Cheon, 2007), 
which is critical to selectivity for the GnRHR-II over GnRHR-I (Wang et al., 2003). GH3 
cells transiently transfected with bullfrog GnRHR-II or rat GnRHR-I were pretreated 
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with GnRH-I prior to SB-75 or Trp-1 treatment. Both antagonists decreased GnRH-
induced IP production in each cell line. However, Trp-1 was 50-fold more potent than 
SB-75 at inhibiting GnRHR-II activity. Conversely, SB-75 was 30-fold more effective at 
reducing GnRHR-I activity than Trp-1 (Table 2.4). Moreover, membrane-binding assays 
revealed that SB-75 exhibited a 12-fold higher binding affinity for GnRHR-I than Trp-1 
(Maiti et al., 2003).  Similarly, CV-1 cells transfected with African green monkey 
GnRHR-II were pretreated with GnRH-II prior to Trp-1 or SB-75 treatment (Wang et al., 
2003). Trp-1, but not SB-75, completely blocked activation of the GnRHR-II. These data 
suggest that Trp-1 is highly selective for GnRHR-II and unlike SB-75, effectively inhibits 
GnRHR-II function.   
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TABLE 2.4. MEAN INOSITOL PHOSPHATE IC
50 
VALUES IN GH3 CELLS 
OVEREXPRESSING EITHER GnRHR-I or GnRHR-II FOLLOWING TREATMENT 
WITH SB-75 OR TRPTORELIX-1 IN THE PRESENCE OF 1 nM GnRH-II
a
. 
 Mean IC
50
 values (± SEM) for Inositol Phosphate
b
 
Receptor Trptorelix-1 SB-75 
GnRHR-I -9.27 ± 0.07 (0.03) -10.74 ± 0.12 
GnRHR-II -6.05 ± 0.17 Partial Inhibition 
 a 
 Adapted from Maiti et al. (2003). 
 b 
 The relative fold change to SB-75 activity is indicated in parentheses.  
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Localization of the GnRHR-II 
Tissue Collection. Animal trials were conducted in accordance with the U.S. 
Meat Animal Research Center (USMARC; Clay Center, Nebraska) Animal Care and Use 
Committee. Mature Chinese Meishan boars (n = 5) were housed individually at 
USMARC and fed 6 lb of feed daily with water available ad libitum. At the USMARC 
slaughter facility, boars (15-17 wk of age) were rendered unconscious by CO2 inhalation, 
exsanguinated and the testes were collected. Next, the head was removed and a lateral 
cranial incision was made, revealing the hypothalamus and anterior pituitary gland within 
the brain for excision. Tissues were snap frozen in liquid nitrogen and stored at -80°C for 
later protein extraction.  Additional sections were collected for immunohistochemistry 
(IHC) by submerging in 4% paraformaldehyde.  Samples were maintained on ice for 
transport and stored at 4°C overnight. The following morning, samples were placed in 
cassettes (Fischer Scientific; Pittsburgh, PA) and stored in 70% ethanol at room 
temperature (RT) until further processing.  
 
Embedding and Sectioning.  For tissue embedding, cassettes containing 
testicular samples were removed from 70% ethanol and rinsed in 100% ethanol 3 times (1 
h each) to remove water and further dehydrate the tissue. Cassettes were then rinsed 3 
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times (1 h each) in CitriSolv (Fischer Scientific). In the case of both the ethanol and 
CitriSolv, the last wash was always in fresh solution. Next, cassettes were placed into 
paraffin overnight in a TISSUE-TEK III embedding machine (Miles Scientific, Sahura 
Fine Technical Company, Naperville, IL). The following morning, tissues were removed 
with forceps and placed in metal forms.  Fresh, hot paraffin was poured over the tissue 
and the back of the cassette was laid into the mold. After chilling for 2 h, the cooled 
paraffin could be removed from the mold and stored at RT. 
After embedding, the tissue was sectioned by first cutting the paraffin mold into a 
trapezoid. Next, 5 µm sections were cut on a Spencer “820” Microtome (American 
Optical Company, Buffalo, NY) and heated in a 37°C water bath to smooth the paraffin. 
Approximately 6 sections were then moved onto an UltraStick slide (Gold Seal Products, 
Portsmouth, NH) and dried on a hot plate (37°C) overnight. After drying, the slides were 
stored in a slide box until further processing. 
 
Immunohistochemistry.  Deparaffinization was achieved by washing slides 
twice through CitriSolv and twice through 100 % ethanol, for 10 min each. Thereafter, 
slides were rinsed for 5 min through 95%, 70%, 50% and 30% ethanol, respectively. Heat 
induced epitope retrieval was achieved by boiling slides in 0.01 M sodium citrate for 15 
min. Slides were then allowed to cool for 1 h and rinsed 3 times in 1X Tris-buffered 
saline (TBS; 25 mM Tris, 150 mM NaCl, 2 mM KCl) for 5 min. After rinsing, individual 
tissue sections were isolated with a PapPen (Research Products International Corp., 
Fredericksburg, VA). Next, the VECTASTAIN ABC-AP kit and its reagents (Vector 
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Laboratories, Burlingame, CA) were used per the manufacturer’s instructions. Briefly, 
slides were blocked with 10% rabbit serum for 20 min, rinsed briefly in 1X TBS and 
excess fluid was wicked away with filter paper. Next, the primary antibody, anti-
GnRHR-II [goat polyclonal, 1:500 (SC- 162889; Santa Cruz Biotechnology, Inc.; Santa 
Cruz, CA)] was diluted (1:100) in 1X TBS and incubated on sections for 30 min in a 
humidified chamber. After incubation, sections were rinsed for 5 min in 1X TBS. Then, 
slides were incubated with the diluted (1:200) biotinylated, anti-goat IgG (H+L) 
secondary antibody provided. Again, slides were rinsed in 1X TBS for 5 min. Next, 
sections were incubated with the ABC-AP reagent, diluted 1:200. Slides were again 
rinsed in 1X TBS for 5 min before the final step, incubation in the alkaline phosphatase 
substrate solution for 30 min. Slides were washed for a final 5 min in tap water. Excess 
water was wicked away and slides were mounted as follows. Approximately 1 drop per 
section of plain Tris-buffered 80% glycerol (warmed to RT) was applied and the sections 
were cover slipped (Fischer Scientific). Slides were sealed with clear nail polish and 
images were obtained using an Olympus (Center Valley, PA) microscope (BX51) and 
camera (DP71). 
 
Immunohistochemical Validation.  The use of the GnRHR-II antibody [goat 
polyclonal, 1:50 (SC- 162889; Santa Cruz Biotechnology)] in IHC was validated prior to 
data collection.  It was determined by protein BLAST (accession number: AS68622) that 
the epitope for this antibody maintained 85% homology for the sus scrofa GnRHR-II, 
specifically the 7-TM isoform. This was also verified by the antibody manufacturer.  
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Further, several concentrations of antibody were examined to test specificity on boar 
testis. The concentration curve was as follows: negative control, 1:200, 1:100, 1:50, 1:25 
and 1:10 (Fig. 3.1). Staining was immediately apparent in the 1:200 dilutions and became 
more intense with higher concentrations. The concentration 1:50 was selected because it 
was the most dilute concentration exhibiting plasma membrane specific staining on 
Leydig cells.   
 
Protein extraction. Protein was extracted from testis and anterior pituitary gland 
samples by homogenizing tissue in 1 ml of RIPA buffer (20 mM Tris, 137 mM NaCl, 
10% glycerol, 1% NP40, 0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA, 1mM PMSF, 
1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail) with a Biospec 
Tissue Tearor (Bartlesville, OK) until completely homogenized. Then, cells were further 
lysed by use of a Dounce Homogenizer (Wheaton Inc., Millville, NJ) 3 times. Samples 
were incubated for 30 min on ice before centrifugation (12,000 x g) at 4ºC using a 
Beckman (Palo Alto, CA) TJ-6 centrifuge. Samples were aliquoted into fresh, pre-chilled 
tubes and stored at -80ºC.   
 The protein concentrations of the testicular lysates were quantified using a 
bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL).  The standard 
curve was comprised of 9 standards, diluted per manufacturer’s instructions.  The 
unknowns were compared to the standard curve to determine a relative protein 
concentration. Briefly, 25 µl of standards or unknowns were pipetted onto a microplate 
(Sarstedt, Inc., Newton, NC) in duplicate. Working reagent (200 µl) was pipetted into 
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each well of the plate. The reagent was prepared by mixing 50 parts BCA Reagent A to 1 
part BCA Reagent B for a final ratio of 50:1, Reagent A:B. The samples were mixed well 
on a plate shaker for 30 s, then covered due to light sensitivity and incubated at 37ºC for 
30 min. Next, the microplate was allowed to cool and light absorbance was measured at 
562 nm on a Spectra Max 250 plate reader (Molecular Devices, Sunnyvale, CA).  
 Protein samples were then prepared for use in Western blot analyses.  
Dithiothreitol (DTT) was mixed with 4X loading dye [LD; 2% Tris (pH 6.8), 28% 
glycerol, 20% SDS and a fleck of Orange G] to a ratio of 10:50 (DTT:LD). This mixture 
was then added to the protein. Samples were vortexed and centrifuged (12,000 x g) for 2 
min. Next, samples were boiled for 5 min at 100ºC, vortexed and centrifuged again 
briefly. Samples were then aliquoted and stored at -80ºC until use. 
 
Western blot.  The gel was prepared by assembling BIO-RAD glass plates 
(Hercules, CA) into a BIO-RAD casting system.  First, acrylamide (10%) was mixed with 
4X Tris-Cl/SDS (pH 8.8; 0.5M Tris-Cl, 0.4% SDS) and 3.5 ml millipore water in a 50 ml 
conical tube. Then, 0.105% ammonium persulfate and 0.75% TEMED were added and 
the solution was inverted slowly to prevent bubble formation. Next, the solution was 
poured into the plates to an approximate height of 4 cm. A thin layer of isobutanol-
saturated water was applied directly on top of the aqueous gel layer to allow for complete 
polymerization. After approximately 15 min, the gel had polymerized completely and the 
isobutanol-saturated water was removed and the gel was rinsed with deionized water 3 
times. The water was wicked away with filter paper and the stacking gel was then poured.  
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The stacking gel consisted of 4% acrylamide, 4X Tris-Cl/SDS (pH 6.8; 1.5mM Tris-Cl 
and 0.4% SDS) and 1.85 ml millipore water (Millipore Corporation, Billerica, MA).  
Then, 0.10% ammonium persulfate and 0.833% TEMED were added and the solution 
was inverted slowly to prevent bubbles and poured on the separating gel until level with 
the top of the plate. A BIO-RAD 15-well comb was then added and the gel polymerized 
for 15 min.  After complete polymerization, running buffer (25 mM Tris, 192 mM 
glycine and 0.1% SDS) was added to the center and sides of the BIO-RAD gel box. Next, 
4 µl of SDS-PAGE ladder (Thermo Scientific, Waltham, MA) was loaded for comparison 
of band sizes. Then, 20 µg of protein was loaded into each well. The gel was then run for 
approximately 1 h (150 V, 30 mA) until good band separation was achieved.  
The gel was removed from the glass plates and placed in transfer buffer (48 mM 
Tris Base, 39 mM glycine, 0.0375% SDS, and 20% methanol) for 10 min. At the same 
time, the wells and dye front were removed from the gel and its dimensions were 
measured. Next, 4 pieces of filter paper (0.34 mm thick) and 1 piece of polyvinylidene 
fluoride membrane (PVDF; Millipore Corporation, Billerica, MA) were cut to the exact 
size of the gel. The filter paper (2 pieces) were soaked in transfer buffer and stacked 
directly on top of each other on an Owl Separation System (Thermo Scientific), followed 
by the gel, PVDF membrane (pre-wetted in 100% methanol) and 2  more pieces of filter 
paper. A roller was used between each layer to smooth the stack and remove air bubbles 
that could interfere with the transfer. Transfer buffer was added to the trough of the 
transfer apparatus, and excess moisture was removed from the plate and stack. The 
protein transfer ran for 1.5 h (200 mA, 20 V). 
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 After transfer, the blot was rinsed in millipore water and nonspecific binding was 
blocked by incubation of the membrane in Odyssey Blocking Buffer (Licor Biosciences, 
Lincoln, NE) for 1 h at RT. Then, blotting membranes were incubated with a goat 
polyclonal primary antibody directed against GnRHR-II (1:1000; SC-162889; Santa Cruz 
Biotechnology), diluted in Odyssey Blocking Buffer with 0.05% Tween-20. Blots were 
left to incubate shaking at 4ºC overnight. After washing 4 times (5 min each) in 1X TBS-
T [TBS (20 nM Tris base, 137 mM NaCl, pH 7.6) and 0.001% Tween-20], blotting 
membranes were incubated with a secondary donkey anti-goat antibody (1:1600; Alexa 
Fluor
® 
680; Invitrogen; Carlsbad, CA) diluted in Odyssey Blocking buffer for 1 h at RT. 
The membranes were then washed 4 times in 1X TBS-T and 4 times in 1X TBS.  Blotting 
results were detected with the Odyssey Scanner and analyzed using Odyssey image 
software (Licor Biosciences).  
After scanning, membranes were stripped with NewBlot stripping buffer (Licor 
Biosciences) for 30 min at RT. Membranes were then blocked for 15 min and reprobed 
with the primary antibody, β-actin (1:2000; SC-1516; Santa Cruz Biotechnology), for 1 h 
at RT. After washing 4 times in 1X TBS-T, blotting membranes were incubated in light-
tight boxes with the secondary donkey anti-goat (1:1600; Alexa Fluor
® 
680; Invitrogen) 
diluted in Odyssey Blocking buffer for 1 h at RT. The membranes were then washed 4 
times in 1X TBS-T and 4 times in 1X TBS.  Again, fluorescence was detected with the 
Odyssey Scanner and analyzed using Odyssey image software.  β-actin served as the 
internal control for Western blot analyses.  Samples were analyzed, normalized to β-actin 
and then expressed as a fold change.  
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 Semen Collection. Semen was collected from mature white crossbred boars 
(UNL Index line; n = 5) using the gloved hand method. Semen was transferred to a 50 ml 
conical tube and centrifuged (800 x g) for 10 min at RT. Seminal plasma was removed 
and stored at -20°C for later analysis. Then, the sperm pellet was layered on a 
discontinuous Percoll gradient of a 90% Percoll solution [90% Percoll, 10% Tyrode’s 
stock (40 mM KCL, 2.92 mM, 0.05% NaH2PO4, 0.02% Hepes buffer, pH 7.3), 1.97 mM 
CaCl2, 0.394 mM, 0.002% lactic acid,  0.002% NaHC03] and a 45% Percoll solution 
[50% of the 90% Percoll solution and 50% TL sperm solution (100 mM NaCl, 3.1 mM 
KCl, 25.0 mM NaHC03, 0.29 mM NaH2Po4H2O, 26 mM Na lactate, 2.107 mM 
CaCl22H20, 0.4 mM MgCl6H20 and 10 mM Hepes; pH 7.3)]. Approximately 2 ml of the 
45% solution was layered on 2 ml of the 90% solution in a 15 ml conical tube. Then, 1 ml 
of the sperm pellet was deposited on top and the tubes were centrifuged (800 x g) for 30 
min at RT. The Percoll gradients were removed and the live sperm were isolated from the 
pellet. Purified spermatozoa were diluted in 1X phosphate buffered saline (PBS; 1.36 M 
NaCl, 1.08 M KCl, 0.1 M Na2HPO4 and 0.017 M KH2PO4) and air-dried on an UltraStick 
slide for later immunocytochemistry. Purified sperm were also flash frozen for protein 
extraction. 
 
Protein extraction.  Samples were lysed by shearing through a 21 gauge needle 
with 200 µl RIPA buffer about 6-7 times. Samples were then passed through a 27 gauge 
needle 5 times, vortexed and allowed to incubate on ice for 45 min. Thereafter, protein 
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was isolated from cellular debris by centrifugation (12,000 x g) at 4ºC using a Beckman 
TJ-6 centrifuge. Samples were aliquoted into fresh, pre-chilled tubes and stored at -80ºC.  
Protein quantification and Western blot sample preparation was performed as described 
above.  
 
Western blot. Western blots of live sperm were performed as previously 
described. However, the blot was not reprobed for β-actin. The primary antibody used 
was directed against GnRHR-II [goat polyclonal, 1:1000 (SC-162889; Santa Cruz 
Biotechnology)]. The secondary antibody was donkey anti-goat (1:1600; Alexa Fluor
® 
680; Invitrogen).  
 
Immunocytochemistry. After air-drying, spermatozoa were fixed with 4% 
paraformaldehyde for 10 min at RT in a humidified chamber. Then, slides were washed 
twice with 1X TBS for 5 min each. Next, slides were exposed to UV light for 30 min to 
quench autofluorescence. Cells were permeabilized with 1X TBS-T (0.5% Tween-20) for 
10 min at RT. Slides were washed 3 times with 1X TBS for 5 min each. Non-specific 
binding was then blocked by incubation with 10% normal rabbit serum diluted in TBS-T 
(0.045% Tween-20) for 30 min at RT. Next, slides were treated with a polyclonal goat 
primary antibody directed against the GnRHR-II (sc-162889; Santa Cruz Biotechnology). 
This antibody was diluted 1:50 with 10% normal serum in TBS-T (0.045% Tween-20) 
and slides incubated overnight at 4°C. The following morning, slides were washed with 
TBS-T (0.05% Tween-20) 3 times for 5 min each. Then, cells were incubated with a 
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rabbit anti-goat Alexa Fluor
®
 488 secondary antibody diluted 1:400 in 10% normal serum 
(TBS plus 0.045% Tween-20) for 1 h at RT in a dark, moist chamber. Finally, slides were 
rinsed 3 times with TBS for 5 min each in the dark. Then, slides were mounted with 
ProLong Gold Antifade Reagent (Invitrogen), cover slipped and sealed with clear nail 
polish. Slides were imaged with an inverted (Olympus IX 81) confocal microscope using 
FITC filter sets. 
 
ELISA. Isolated seminal plasma as well as testis, anterior pituitary gland and 
hypothalamus homogenates were assayed for a precursor form of GnRH-II by a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit, specific to the 
pig (Cat #: CSE-EL009636PI; Cusabio; Hubei, China). Seminal plasma samples were 
from mature, white crossbred boars (UNL Index line). Testis, anterior pituitary gland and 
hypothalamus samples were collected from mature, Chinese Meishan boars, snap frozen 
and stored at -80°C. Tissue was homogenized per manufacturer’s instructions. Briefly, 
100 mg of tissue was rinsed with 1X PBS and then homogenized in 1 ml of 1X PBS, and 
stored overnight at -20°C. After thawing and freezing again (to break the cell 
membranes), the samples were centrifuged at (5,000 x g) for 5 min at 4°C. The 
supernatant was removed and frozen at -80°C until assay.  Homogenate samples were 
thawed fully and centrifuged briefly again prior to use in the assay. 
 The ELISA was performed according to the manufacturer’s instructions. Prior to 
assay, all reagents and samples were allowed to warm for 30 min and a 1X wash buffer 
was prepared. First, the standard curve was added to the plate by pipetting 50 µl of each 
74 
 
standard into each well (0, 40, 160, 640, 2,000 and 8,000 pg/ml), in duplicate. An 
additional standard was also added (20 pg/ml).  Two wells were left blank to serve as 
non-specific binding (NSB) wells. Then, 50 µl of the unknown samples (seminal plasma 
or tissue homogenates) were added, in duplicate. Immediately following, 50 µl of the 
provided horseradish peroxidase-conjugate was added to each well (except the NSB 
wells), followed by 50 µl of the antibody. The plate was shaken gently to mix and then 
incubated at 37°C for 1 h. Next, each well was aspirated and washed with 200 µl of the 
1X wash buffer solution using a multi-channel pipette. The wash buffer was left for 10 s 
before subsequent aspiration. This was repeated a total of 3 times, ensuring all liquid was 
decanted between each wash. After the last wash, the plate was inverted and blotted on 
filter paper to remove any remaining wash buffer. Next, 50 µl of substrate A was added 
to each well, followed by 50 µl of Substrate B. The plate was then mixed gently on a 
plate shaker and allowed to incubated in the dark at 37°C for 15 min. Then, 50 µl of the 
Stop Solution was added to each well. The reagents were mixed by gentle tapping on the 
plate. The optical density was immediately read using a Wallac 1420 Victor
2  
microplate 
reader (Perkin Elmer; Waltham, MA) set to 450 nm. The data were interpolated based on 
the standard curve using a four parameter logistic (4-PL) curve fit per the manufacturer's 
instructions. The minimum sensitivity of the assay was 20 pg/ml. The intra-assay 
coefficient of variation between pooled samples was 10%.  
 
Testicular Explants 
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Materials. Chinese Meishan boars (n = 7) were transported to the USMARC 
slaughter facility the morning of collection.  Animals were rendered unconscious by 
inhalation of 100% CO2 and were humanely euthanized by exsanguination. Whole testes 
were collected, weighed and a random section of the parenchyma was removed and 
minced finely.  Approximately 400 mg of minced tissue was incubated in 50 ml conical 
tubes (Corning Inc., Corning, NY) with 5 ml of TC199 (with Earle's salts and NaHCO3; 
Sigma-Aldrich; St. Louis, MO). The media was buffered with a final concentration of 25 
mM Hepes (N-2-hydroxy-ethyl-piperazine-N-2ethane sulfonic acid). Tissue explants 
were pre-incubated for approximately 2.5 h during transit. Tissue was exposed to a 95% 
O2 and 5% C02 atmosphere, maintained at 37ºC and disrupted every 10 min to prevent 
tissue aggregation. Upon return to UNL, the media was decanted and replaced with fresh 
TC199 (25 mM Hepes), and explants were randomly assigned to treatment.  
 
Treatments. At time 0, explant cultures were exposed to either vehicle (water) or 
1 µM GnRH-II (Bachem Inc., Torrance, CA). Administration of vehicle or GnRH-II at 
this time point was considered a pretreatment. Media was collected (250 µl) 1 h after 
pretreatment from all cultures, then explants were treated.  Treatments were either vehicle 
(water) or 1 I.U. human chorionic gonadotropin (hCG; Sigma-Aldrich). Therefore, all 
combinations (pretreatment + treatment) resulted in 4 different treatments: control 
(vehicle + vehicle), hCG alone (vehicle + hCG), GnRH-II pretreatment without hCG 
(GnRH-II + vehicle) or GnRH-II pretreatment with hCG (GnRH-II + hCG). After 
treatment, media was collected 120, 180 and 240 min later (Fig. 3.2).  Media was 
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Figure 3.2. Schematic indicating time of pretreatment (PRE; 0 or 1 µM GnRH-II), 
treatment  (TRT; 0 or 1 I.U. hCG), media collection (hash mark) and tissue collection 
for testicular explants.  
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immediately frozen after each collection and subsequently stored at -20ºC until further 
processing. Tissue was snap frozen in liquid nitrogen and stored at -80°C until protein 
extraction and Western blot analyses.  
 
Protein Extraction. Testis protein was extracted by homogenizing tissue in 1 ml 
RIPA buffer with a Biospec Tissue Tearor until completely homogenized. Then, cells 
were further lysed by use of a Dounce Homogenizer (Wheaton, Inc.) 3 times. Samples 
were incubated for 30 min on ice before centrifugation (12,000 x g) at 4ºC using a 
Beckman TJ-6 centrifuge. Samples were aliquoted into fresh, pre-chilled tubes and stored 
at -80ºC.  Protein concentration was then quantified by BCA assay and samples were 
processed for use in Western blots, as described previously.  
 
Western Blot.  Western blots were performed as described previously. However, 
for these testis samples, 2 different primary antibodies were used. Either GnRHR-II [goat 
polyclonal, (1:1000; SC-162889; Santa Cruz Biotechnology)] or LH receptor [rabbit 
polyclonal (1:300; SC-25828; Santa Cruz Biotechnology)]. The secondary antibodies 
used were either donkey anti-goat (1:1600; Alexa Fluor
® 
680; Invitrogen) or goat anti-
rabbit (1:1600; Alexa Flour
® 
800; Invitrogen). As described previously, blots were 
stripped and reprobed for β-actin to serve as an internal loading control. 
 
Radioimmunoassay.  Total testosterone levels were determined using a Total 
Testosterone Coat-a-Count RIA kit (Siemens Healthcare Diagnostics, Los Angeles, CA) 
78 
 
in accordance with the manufacturer’s instructions. This kit has been previously validated 
in the pig (Oskam et al., 2010; Ashworth et al., 2011) and prior to use in this trial was 
examined for parallelism in measuring testis explant media. The minimum sensitivity of 
the assay was 0.16 ng/ml and the intraassay coefficient of variation was 8%.  Briefly, 50 
µl of zero calibrator (0 ng/ml testosterone) was added to 2 (duplicate) uncoated 12x75 
mm polypropylene tube non-specific binding (NSB) tubes and 2 Total Testosterone Ab-
Coated tubes for maximum binding.  Then, 50 µl of each remaining calibrator (B-F; 0.16, 
0.96, 4.14, 7.92 and 16.85 ng/ml testosterone, respectively) were pipetted into Total 
Testosterone Ab-Coated tubes (Specific binding; Bø) taking care to pipette directly into 
the bottom of all tubes. Next, media samples were diluted 1:5 with Siemens zero 
calibrator solution (as per manufacturer’s instructions).  This dilution was used based on 
previous trials. Then, 1 ml of testosterone radioactively labeled with I
125
 was added to 
every tube and tubes were covered with parafilm, vortexed for 30 s and incubated in a 
37°C waterbath for 3 h. The NSB tubes containing only 1 ml 
125
I Total Testosterone were 
set aside for total counts.  Following incubation, liquid was decanted thoroughly (except 
the total counts tubes) and allowed to drain for 2-3 min. Finally, samples were counted 
using an APEX Automativ gamma counter (ICN Micromedia Systems, Horsham, PA) for 
1 min.  Percent binding was then determined using the following equation: [(Bø-
NSB)/TC)]*100 = % binding. Data were analyzed and fit to the standard curve using 
Graphpad PRISM (San Diego, CA) to determine relative testosterone levels. 
 
Boar Trials 
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Animals.  The following animal trial was conducted in accordance with the 
USMARC Animal Care and Use of Committee. Mature Chinese Meishan boars were 
housed individually at USMARC and fed 6 lb of feed daily with water available ad 
libitum. Mature boars were randomly assigned to treatments. The experiment was 
performed over a 2 wk time period in a cross-over design, such that each boar received 
each treatment once, 1 wk apart.  Catheterization of boars was conducted according to 
Ford and Maurer (1978) at USMARC (Appendix I), approximately 4-5 d prior to 
initiation of the trial.  
 
Experiment 1: GnRH Agonist Trial. On the day of treatment, blood samples (10 
ml) were collected every 20 min for 2 h to obtain a baseline hormonal profile. Then, 
boars (n = 5/treatment) were given I.V. infusions of either a GnRH-I agonist (D-ala
6
 
GnRH-I; 150 ng/kg BW) or GnRH-II agonist (D-ala
6
 GnRH-II; 150 ng/kg BW), both 
dissolved in sterile saline. Blood samples were drawn every 10 min for 30 min and every 
20 min for 270 min thereafter (Fig. 3.3). During blood sampling, catheters were kept 
clear by injecting 2 ml of 3.5% sodium citrate prior to blood draws. Once blood was 
evident upon drawback, a heparinized vacutainer was utilized to collect 10 ml of blood. 
Tubes were inverted slowly to prevent clotting and red blood cell lysis. Following blood 
collection, 3 ml of heparinized saline was injected and the catheter cap was cleaned with 
100% ethanol before being replaced. Blood samples remained at 4°C until centrifugation 
(12,000 x g) and plasma was collected and stored at -20°C until analysis.
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Figure 3.3. Schematic of boar GnRH agonist trial indicating treatment (TRT) and time 
of blood sample (hash mark). At 0 min, blood was collected prior to administration of 
treatment. 
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Testosterone and LH levels were measured by radioimmunoassay (RIA) in Dr. Clay 
Lents’ laboratory at USMARC, according to Ford et al. (2001) and Kesner et al. (1987), 
respectively. Minimum sensitivities were 0.1 ng/ml and 0.1 ng/ml for LH and 
testosterone, respectively, and corresponding intraassay coefficients of variation for 
pooled samples averaged 7.3 and 9%, respectively.  
 
Animals. All remaining animal trials were conducted at UNL in accordance with 
the UNL’s Institutional Animal Care and Use Committee (IACUC). Mature white cross 
bred boars (UNL Index line) were housed individually with ad libitum access to water 
and fed approximately 5 lb of feed daily.  At least 3 days prior to trial initiation, boars 
were cannulated in the jugular vein according to either Barb et al. (1982) or Ford and 
Maurer (1978). 
 
Experiment 2: GnRH Antagonist Trial. Boars were randomly assigned to be 
treated with either a specific GnRH-I antagonist (SB-75; 5 µg biologically active 
compound/kg BW; UNL Protein Core; n = 9), or a specific GnRH-II antagonist, 
Trptorelix (Trp-1; 5 µg/kg BW; AnyGen, Gwangju, Korea; n = 10). The experiment was 
performed over a 2 wk time period in a cross-over design, such that each boar received 
each treatment once, 1 wk apart. SB-75 was dissolved in 0.9% sterile saline and Trp-1 
was dissolved in solution per manufacturer’s instructions.  Briefly, Trp-1 was first 
dissolved in 5% dimethylacetamide, then mixed with 40% propylene glycol and finally 
diluted in 55% millipore water.  
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Blood (9 ml) was drawn 30 min and immediately prior to treatment. Treatments 
were then given I.M. in the neck. Each animal also received the vehicle of the opposite 
treatment. Next, blood sampling occurred every 30 min for 3 h (30, 60, 90, 120, 150, 180 
min), at 6 h and at 12 h. Thereafter, blood was taken every 12 h for 48 h (Fig. 3.4).  
During blood sampling, catheters were kept clear by injecting 5 ml of 3.5% sodium 
citrate prior to blood draws. Once blood was evident upon drawback, 9 ml was collected 
and the cannula was flushed again with 3 ml heparinized saline.  The catheter cap was 
cleaned with 100% ethanol before being replaced. The S-Monvette serum blood tubes 
(Sarstedt, Nümbrecht, Germany) utilized were inverted slowly to distribute silicate beads, 
aiding in clotting and preventing red blood cell lysis. Blood samples remained at 4°C for 
1-24 h until centrifugation (2,000 x g), at which time serum was collected and stored at -
20°C until RIA analysis. 
 
Experiment 3: SB-75 + GnRH Agonists Trial.  First, blood (9 ml) was collected 
20 min, 10 min and immediately prior to treatment. Then, each boar was treated with the 
GnRH-I antagonist, SB-75 (5 µg biologically active compound/kg BW; UNL Protein 
Core). Approximately 7.5 h later, blood was collected to confirm the activity of SB-75. 
Then, boars (n = 5) were given I.V infusions of either a GnRH-I agonist (D-ala
6
 GnRH-I; 
150 ng/kg BW; Bachem) or the GnRH-II agonist (D-ala
6
 GnRH-II; 150 ng/kg BW; 
Anygen). Blood samples were then drawn every 10 min for 30 min and then every 20 
min for 4 h (Fig. 3.5). During blood sampling, catheters were kept clear by injecting 2 ml 
of 3.5% sodium citrate prior to blood draws. Once blood was evident upon drawback, S-
83 
 
Hour - 0.5 0 0.5 1.5 2 1 2.5 12 24 36 48 6 3 
 
TRT 
Figure 3.4. Schematic of GnRH boar antagonist trial indicating treatment (TRT) and 
time of blood sample (hash mark). At 0 h, blood was collected prior to administration 
of treatment. 
84 
 
Minutes  -460 -450 -470 0 10 20 30 60 80 100 120 150 170 190 210 230 250 270 
 
TRT 
Figure 3.5. Schematic of SB-75 + GnRH agonist trial indicating SB-75 
administration, treatment (TRT) and time of blood sample (hash mark). At 0 min, 
blood was collected prior to administration of GnRH analogues. 
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Monvette serum blood tubes (Sarstedt) were utilized to collect 9 ml of blood. Tubes were 
inverted following blood collection, 3 ml of sodium citrate was injected and the catheter 
cap was cleaned with 100% ethanol before being replaced. Blood samples remained at 
4°C until centrifugation (12,000 x g) and serum was collected and stored at -20°C until 
RIA analysis. This experiment was a crossover design such that each animal received 
each treatment, 1 week apart.  
 
Experiment 4: Intratesticular GnRH Injection Trial. Approximately 9 ml of 
blood was collected 20 min, 10 min and immediately prior to I.V. administration of the 
anesthetic, sodium pentothal (3 mg/lb BW). The use of pentothal as an anesthetic has 
been previously shown not to alter LH or testosterone concentrations in gilts and barrows 
(Clapper, 2008). Once the animal was sedated, either a GnRH-I agonist (D-ala
6
 GnRH-I; 
Bachem), a GnRH-II agonist (D-ala
6
 GnRH-II; Anygen) or a saline control was 
immediately injected transscrotally. Each testis was injected 3 times (ventral to dorsal, 
approximately 2 in apart), ~1 ½ in into the parenchyma with a 20 gauge, 1 ½ in 
hypodermic needle. The GnRH-I (50 ng) or GnRH-II (50 ng) agonists were dissolved in 
1 ml of sterile saline, therefore accumulating to a total dose of 300 ng per animal. 
Thereafter, blood was collected every 10 min for 40 min and then every 20 min for 240 
min (Fig. 3.6). During blood sampling, catheters were kept clear by injecting 2 ml of 
3.5% sodium citrate prior to blood draws. Once blood was evident upon drawback, S- 
Monvette serum blood tubes (Sarstedt) were utilized to collect 9 ml of blood. Tubes were 
inverted slowly to aid in clotting and red blood cell lysis. Following blood collection, 3 
86 
 
Minutes - 20 -10 0 20 30 10 40 120 180 200 220 240 80 60 
 
TRT 
Figure 3.6. Schematic of boar intratesticular GnRH injection trial indicating 
treatment (TRT) and time of blood sample (hash mark). At 0 min, blood was 
collected prior to administration of treatment. 
87 
 
ml of sodium citrate was injected and the catheter cap was cleaned with 100% ethanol 
before being replaced. Blood samples remained at 4°C until centrifugation (12,000 x g) 
and serum was collected and stored at -20°C until RIA analysis. This experiment was a 
crossover design such that each animal received each treatment 4 days apart.   
 
Radioimmunoassay.  After completion of the experiment 2, 3 and 4, testosterone 
concentrations were determined using a Total Testosterone Coat-a-Count RIA kit 
(Siemens Healthcare Diagnostics) in accordance with the manufacturer’s instructions. 
This kit has been validated in the pig (Oskam et al., 2010; Ashworth et al., 2011) and 
parallelism was confirmed previously in our lab. 
Briefly, 50 µl of zero calibrator (0 ng/ml testosterone) was added to 2 (duplicate) 
uncoated 12 x 75 mm polypropylene, non-specific binding (NSB) tubes and 2 Total 
Testosterone Ab-Coated tubes for maximum binding.  Then, 50 µl of each remaining 
calibrator (B-F; 0.16, 0.96, 4.14, 7.92 and 16.85 ng/ml testosterone, respectively) were 
pipetted into Total Testosterone Ab-Coated tubes (Specific binding; Bø), taking care into 
pipette directly to the bottom of all tubes. Two additional standards were added to 
increase the accuracy of the curve (0.08 and 0.04 ng/ml). After pipetting samples into 
each tube, 1 ml of testosterone radioactively labeled with I
125
 was added to every tube 
and tubes were covered with parafilm, vortexed for 30 s and incubated in a 37°C 
waterbath for 3 h. The NSB tubes containing only 1 ml 
125
I labeled testosterone were set 
aside for total counts.  Following incubation, liquid was decanted thoroughly (except the 
total counts tubes) and allowed to drain for 2-3 min. Finally, samples were counted using 
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an APEX Automativ Gamma counter (ICN Micromedia Systems) for 1 min. The 
minimum sensitivity of the assay was 0.04 ng/ml and the intraassay coefficient of 
variation was 10.2%.  Percent binding was then determined using the following equation: 
[(Bø-NSB)/TC)]*100 = % binding. Data were analyzed and fit to the standard curve 
using Graphpad PRISM to determine relative testosterone levels. 
 Relative LH values were determined by Dr. Clay Lents’ laboratory at USMARC 
according to Kesner et al. (1987). The minimum sensitivity of the assay was 0.1 ng/ml 
LH and the intraassay coefficient of variation was 10%. 
 
Statistical Analysis 
 Data were analyzed using the Statistical Analysis System (SAS; Cary, NC). 
Western blot data were confirmed to be normally distributed and analyzed using the 
GLM procedure with replication as a random effect. Tissue explant RIA data was 
analyzed by the MIXED procedure with replication as a random effect.  Statistical 
evaluation for all in vivo boar trials was performed using the MIXED procedure of SAS 
with time as a repeated measure. Day of treatment and assay were added as random 
effects.  The Shapiro-Wilk test for normality indicated that means for RIA data from 
explant and boar trials were not normally distributed, thus, these means were 
logarithmically transformed and compared using least-significant differences (P < 0.05). 
Non-transformed means, however, were presented in the results sections (Chapter IV) for 
comparison.  
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CHAPTER IV 
 
The role of GnRH-II and its receptor in testicular function  
 
Abstract 
 
The highly conserved, second mammalian isoform of GnRH (GnRH-II) has been linked 
to regulation of cell proliferation, feed intake, and the interaction between energy balance 
and reproductive behavior. In contrast to the native form of GnRH (GnRH-I), GnRH-II is 
an inefficient modulator of gonadotropin secretion. Unlike many species, a functional 
receptor (GnRHR-II) specific to this ligand has been discovered in the pig that may be 
directly involved in testosterone production. Therefore, the objective of this study was to 
identify the role of GnRH-II and its receptor in testicular function. First, Western blot 
analysis of tissues from mature, Chinese Meishan (MS) boars revealed 6-fold more 
GnRHR-II protein in the testis than anterior pituitary gland. GnRH-II levels determined 
by ELISA were highest in testis (1,321 ± 52.5 pg/ml), intermediate in pituitary (393 ± 
58.7 pg/ml) and lowest in hypothalamus (220 ± 67.7 pg/ml) tissue homogenates. 
Immunohistochemistry of testicular tissue indicated that the GnRHR-II was located on 
the plasma membrane of Leydig cells within the interstitium as well as germ cells. 
Second, immunocytochemistry demonstrated that GnRHR-IIs were localized to the neck 
region of purified spermatozoa from mature, white crossbred (WC) boars. Consistent 
with this, GnRH-II was also detected in seminal plasma (225 ± 27.3 pg/ml) via ELISA. 
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Third, testicular tissue explants from MS boars exposed to 1 µM GnRH-II secreted 
testosterone similarly to hCG treated (1 I.U.) tissues, without influencing GnRHR-II or 
LH receptor protein levels. Finally, 4 in vivo experiments were performed on MS or 
white crossbred (WC) boars surgically fitted with jugular cannulae. In Exp. 1, plasma 
testosterone concentrations were elevated following I.V. treatment of MS males with 
either a
 
GnRH-I (D-ala
6 
GnRH-I) or GnRH-II (D-ala
6 
GnRH-II) agonist (150 ng/kg BW), 
although GnRH-II induced changes in LH levels were not correlated with testosterone 
production. In Exp. 2, I.M. treatment of WC males with a GnRH-I (SB-75; 5 µg 
biologically active compound/kg BW) or GnRH-II (Trp-1; 5 µg/kg BW) antagonist 
suppressed testosterone, but not LH, secretion.  In Exp. 3, serum testosterone 
concentrations increased in WC males after I.M. treatment with SB-75 followed by I.V. 
infusion of either
 
GnRH-I or -II agonist, despite the inability of GnRH-II to induce LH 
secretion. In Exp. 4, intratesticular injection of WC males with GnRH-I, GnRH-II or 
saline resulted in GnRH-II-induced stimulation of testosterone production without 
increasing LH levels.  Taken together, these data suggest that GnRH-II directly impacts 
testosterone production via binding to the GnRHR-II on Leydig cells, bypassing LH 
production by the anterior pituitary gland. 
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Introduction 
 
Boar subfertility is a source of economic loss often overlooked (Foxcroft et al., 
2008) since the swine industry has adopted techniques to compensate for subfertility.  
Commonly, semen collections are pooled from multiple sires and packaged in excess of 3 
billion sperm cells per dose (Dyck et al., 2011).  Traditionally, semen samples undergo 
conventional analyses (semen volume, concentration, morphology and progressive 
motility) immediately after collection to determine fertility (Amann et al., 1995). While 
these parameters are useful for identifying infertile boars (Flowers, 1997; Xu et al., 
1998), they may not truly indicate the reproductive status of a boar (Correa et al., 1997; 
Brahmkshtri et al., 1999). Therefore, more screening procedures are needed to identify 
subfertile boars to improve reproductive efficiency. 
The classical form of GnRH (GnRH-I) is a key regulator of testosterone 
production through stimulation of luteinizing hormone (LH) secretion from the anterior 
pituitary gland. GnRH-I and its receptor (GnRHR-I) have also been detected in the testes 
of males; specifically, GnRHR-I has been detected in Leydig cells (Iwashita and  Catt, 
1985; Jegou et al., 1985; Nikula and  Huhtaniemi, 1988; Petersson et al., 1989; Reinhart 
et al., 1992; Kakar et al., 1992), whereas GnRH-I may be produced by Sertoli cells 
(Sharpe and  Fraser, 1980; Verhoeven and  Cailleau, 1985; Sharpe and  Cooper, 1987; 
Saint Pol et al., 1988).  Moreover, the interaction between GnRH-I and its receptor in the 
testis have been implicated in localized regulation of testosterone production, 
independent of LH (Sharpe et al., 1983; Verhoeven and  Cailleau, 1985; Jegou et al., 
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1985; Petersson et al., 1989; Bahk et al., 1995; Lin et al., 2010; Anjum et al., 2012). For 
example, rats injected with GnRH-I directly into the testis experienced an immediate 
increase in serum testosterone concentration, although LH levels were unaffected (Sharpe 
et al., 1983).  Further, short-term GnRH-I treatment of rat primary Leydig cell cultures 
increased testosterone production (Sharpe and  Cooper, 1982b), whereas long-term 
exposure decreased testosterone secretion, suggesting downregulation of the GnRHR-I.   
Recently, a new mammalian form of GnRH (GnRH-II) was discovered, differing 
from GnRH-I by 3 amino acids and expressed in almost every tissue (Kasten et al., 1996; 
Millar, 2003).  GnRH-II also maintains its own specific receptor (GnRHR-II) and, like 
GnRHR-I, is a 7-transmembrane (TM), G-protein coupled receptor (GPCR; Neill et al., 
2001; Millar et al., 2001). Interestingly, not all species produce a functional GnRHR-II 
due to coding errors (Stewart et al., 2009). However, the sequence for a functional 
receptor has been discovered in shrews, old world monkeys and swine (Stewart et al., 
2009). In these species, the function of GnRH-II and its receptor is unclear (Neill et al., 
2004), but evidence suggests GnRH-II is not an efficient modulator of gonadotropin 
secretion (Okada et al., 2003). Instead, GnRH-II and its receptor have been linked to feed 
intake (Kauffman and  Rissman, 2004b), cell proliferation in peripheral reproductive 
tissues (Chou et al., 2002), and the interaction between energy balance and sexual 
behavior in females (Kauffman and  Rissman, 2004a). In addition, new evidence suggests 
that GnRH-II might also be involved in male reproductive function.  
Bowen et al. (2006) discovered that boars immunized against GnRH-II displayed 
reduced levels of testosterone, independent of alterations in gonadotropin secretion. 
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Similarly, primary Leydig cell cultures from GnRH-II immunized boars secreted less 
testosterone compared to control boars upon LH challenge. Additionally, boars treated 
with a specific GnRH-I antagonist (SB-75; cetrorelix) daily for 4 d displayed suppressed 
testosterone levels for the duration of treatment, whereas LH levels returned to basal after 
only 36 h of treatment (Zanella et al., 2000). Moreover, testicular explant cultures treated 
with human chorionic gonadotropin (hCG) in the presence of SB-75 produced less 
testosterone compared to controls.  
Given that GnRHR-I has never been detected in the boar testis (Zanella et al., 
2000), our hypothesis is that the interaction between GnRH-II and its receptor can 
directly stimulate testosterone secretion from the boar testis via an autocrine or paracrine 
mechanism. Here, we demonstrate that GnRH-II and its receptor are highly abundant in 
the testis compared to the anterior pituitary gland, localized to the plasma membrane of 
Leydig cells and germ cells. Furthermore, GnRH-II levels were highest in the testis, 
intermediate in the anterior pituitary gland and lowest in the hypothalamus.  Testis 
explants treated with GnRH-II alone secreted testosterone to a similar level as hCG 
treated tissues, without upregulating the LH receptor. Moreover, boars challenged with 
GnRH-I and -II secreted testosterone similarly, however, GnRH-II stimulated 
testosterone levels were not correlated with LH concentrations. Additionally, 
administration of a GnRH-I antagonist prior to GnRH-II treatment prevented LH, but not 
testosterone, production. Consistent with this, GnRH-II injected directly into the testis 
stimulated testosterone, but not LH, production. Finally, the GnRHR-II was localized to 
the neck region of spermatozoa, corresponding to GnRH-II presence in seminal plasma. 
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Materials and Methods 
 
Localization of GnRH-II and GnRHR-II 
Tissue Collection. Animal trials were conducted at the U.S. Meat Animal 
Research Center (USMARC; Clay Center, Nebraska) in accordance with the Animal Care 
and Use Committee. Mature Chinese Meishan boars (n = 5) were housed individually at 
USMARC and fed 6 lb of feed daily with water available ad libitum. Boars (15-17 wk of 
age) were euthanized and the hypothalamus, anterior pituitary gland and testes were 
collected. Tissues were either snap frozen in liquid nitrogen and stored at -80°C or fixed 
in 4% paraformaldehyde for immunohistochemistry (IHC).   
 
Immunohistochemistry. Tissue isolated from the testes was dehydrated with 
100% ethanol, cleared with CitriSolv (Fischer Scientific, Pittsburgh, PA), paraffin 
embedded, sectioned (5 µm) and mounted on UltraStick slides (Gold Seal Products, 
Portsmouth, NH). Epitope retrieval was achieved by boiling slides containing sections of 
testicular tissue in 0.01 M sodium citrate for 15 min. Non-specific binding was blocked 
with 10% rabbit serum for 20 min and slides were incubated for 30 min at room 
temperature (RT) with the primary antibody, anti-GnRHR-II (goat polyclonal; SC-
162889; Santa Cruz Biotechnology, Santa Cruz, CA), diluted (1:100) in 1X TBS (25 mM 
Tris, 150 mM NaCl, 2 mM KCl). Next, alkaline phosphatase detection was performed 
using the VECTASTAIN ABC-AP kit (Vector Laboratories, Burlingame, CA) per 
manufacturer’s instructions. Finally, slides were mounted with Tris-buffered 80% 
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glycerol and imaged using an Olympus (Center Valley, PA) microscope (BX51) and 
camera (DP71). 
 
Semen Collection. Semen was collected from mature, white crossbred boars 
(UNL Index line; n = 5) using a gloved hand method. Semen was centrifuged (800 x g) 
for 10 min at RT and seminal plasma was removed and stored at -20°C for later analysis. 
Then, 1 ml of the semen pellet was layered on a discontinuous Percoll gradient 
containing 2 ml of a 90% Percoll solution [90% Percoll, 10% Tyrode’s stock (40 mM 
KCL, 2.92 mM, 0.05% NaH2PO4, 0.02% Hepes buffer, pH 7.3), 1.97 mM CaCl2, 0.394 
mM, 0.002% lactic acid, 0.002% NaHC03] and 2 ml of a 45% Percoll solution (50% of 
the 90% Percoll solution and 50% TL sperm solution; 100 mM NaCl, 3.1 mM KCl, 25.0 
mM NaHC03, 0.29 mM NaH2Po4H2O, 26 mM Na lactate, 2.107 mM CaCl22H20, 0.4 mM 
MgCl6H20 and 10 mM Hepes; pH 7.3) layered on top of the 90% Percoll solution in a 15 
ml centrifuge tube. The tubes were centrifuged (800 x g) for 30 min at RT and purified 
spermatozoa were collected from the pellet. Samples were then diluted in 1X phosphate 
buffered saline (PBS; 1.36 M NaCl, 1.08 M KCl, 0.1 M Na2HPO4 and 0.017 M KH2PO4) 
and either air-dried on UltraStick slides (Gold Seal Products) for later 
immunocytochemistry or flash frozen. 
 
ELISA. Isolated seminal plasma as well as testis, anterior pituitary gland and 
hypothalamus homogenates were assayed for a precursor form of GnRH-II with a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit, specific to the 
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pig (Cat. # CSE-EL009636PI; Cusabio; Hubei, China). The ELISA was performed 
according to the manufacturer’s instructions. Briefly, a standard curve (0, 20, 40, 160, 
640, 2,000 and 8,000 pg/ml) was added to the plate, followed by the unknown samples 
(seminal plasma or tissue homogenates). Next, horseradish peroxidase-conjugate was 
added to each well, followed by the primary antibody. The plate was mixed and 
incubated at 37°C for 1 h. Subsequently, each well was aspirated and washed with 1X 
Wash Buffer Solution and then Substrate A was added to each well, followed by 
Substrate B. The plate was then mixed and incubated in the dark at 37°C for 15 min. 
Finally, the Stop Solution was added to each well, the plate was mixed and the optical 
density was immediately read using a Wallac 1420 Victor
2  
microplate reader (Perkin 
Elmer; Waltham, MA) at 450 nm. The data were interpolated based on the standard curve 
using a 4 parameter logistic (4-PL) curve fit per manufacturer’s instructions. The 
minimum sensitivity of the assay was 20 pg/ml. The intraassay coefficient of variation 
was 10%. 
 
Immunocytochemistry. After air-drying, spermatozoa were fixed with 4% 
paraformaldehyde for 10 min at RT in a humidified chamber. Then, slides were exposed 
to UV light for 30 min to quench autofluorescence. Cells were permeabilized with 1X 
TBS-T (0.5% Tween-20) for 10 min at RT. Non-specific binding was blocked by 
incubation with 10% normal rabbit serum diluted in TBS-T (0.045% Tween-20) for 30 
min at RT. Cells were incubated in a humidified chamber at 4°C overnight with a 
polyclonal goat primary antibody directed against GnRHR-II (1:50; SC-162889; Santa 
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Cruz Biotechnology), diluted with 10% normal serum in TBS-T (0.045% Tween-20). 
Next, slides were incubated with a rabbit anti-goat Alexa Fluor
®
 488 secondary antibody 
(Invitrogen, Carlsbad, CA) diluted 1:400 in 10% normal serum for 1 h at RT. After all 
steps, slides were washed with 1X TBS-T. Finally, slides were rinsed with TBS and 
mounted with ProLong Gold Antifade Reagent (Invitrogen), and imaged with an inverted 
confocal microscope (Olympus IX 81) using FITC filter sets. 
 
Testicular Explants 
Materials. Chinese Meishan boars (n = 7) were euthanized and whole testes were 
collected.  Approximately 400 mg of finely minced tissue was incubated in 5 ml of 
TC199 (with Earle's salts and NaHCO3; Sigma-Aldrich, St. Louis, MO) buffered with a 
final concentration of 25 mM Hepes. Tissue was exposed to a 95% O2 and 5% CO2 
atmosphere and maintained at 37ºC for 1 h. This preincubation was necessary as 
testosterone is released from the tissue during dissection and can mask hormone induced 
testosterone secretion (Allrich et al., 1983). Then, the media was decanted and replaced 
with fresh TC199 and explants were randomly assigned to a treatment. 
 
Treatments. At time 0, explant cultures were exposed to either vehicle (water) or 
1 µM GnRH-II (Bachem Inc., Torrance, CA) as a pretreatment. Media (250 µl) was 
collected 1 h after pretreatment from all cultures and explants were treated with either 
vehicle (water) or 1 I.U. human chorionic gonadotropin (hCG; Sigma-Aldrich). 
Therefore, 4 combinations (pretreatment + treatment) were tested: control (vehicle + 
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vehicle), hCG alone (vehicle + hCG), GnRH-II pretreatment without hCG (GnRH-II + 
vehicle) or GnRH-II pretreatment with hCG (GnRH-II + hCG). After treatment, media 
(250 µl) was collected 120, 180 and 240 min later.  Media was immediately frozen after 
each collection and subsequently stored at -20ºC, whereas tissue was snap frozen and 
stored at -80°C.  
 
Western Blot. Protein was extracted from explant, testis and anterior pituitary 
gland tissues by homogenization in 1 ml of RIPA buffer (20 mM Tris, 137 mM NaCl, 
10% glycerol, 1% NP40, 0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA, 1mM PMSF, 
1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail) per 100 mg of 
tissue. Spermatozoa protein was extracted by homogenizing samples (100 µl) in 200 µl of 
RIPA buffer.  The protein concentration of the lysates was quantified using a 
bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL) per manufacturer’s 
instructions.  Dithiothreitol (DTT) was mixed with 4X loading dye [LD; 2% Tris (pH 
6.8), 28% Glycerol, 20% SDS, a fleck of Orange G] to a ratio of 10:50 (DTT:LD) and 
combined with the extracted protein 1:3 (LD:protein).  
Proteins were separated using SDS-PAGE (10%) and transferred to 
polyvinylidene difluoride (PVDF) membrane. After transfer, non-specific binding was 
blocked by incubation in Odyssey Blocking Buffer (Licor Biosciences, Lincoln, NE) for 
1 h at RT. Then, membranes were probed with a goat polyclonal primary antibody 
directed against GnRHR-II (1:1000; SC-162889; Santa Cruz Biotechnology), diluted in 
Odyssey Blocking Buffer with 0.05% Tween-20 shaking at 4ºC overnight. Next, 
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membranes were incubated with a secondary donkey anti-goat antibody (1:1600; Alexa 
Fluor
® 
680; Invitrogen) in Odyssey Block for 1 h at RT. Between each step, the 
membranes were washed in TBS-T. On separate Western blots, protein from explant 
tissue was also probed with an antibody directed against the LH receptor (LHR; rabbit 
polyclonal; 1:300; SC-25828; Santa Cruz Biotechnology) followed by a secondary goat 
anti-rabbit antibody (1:1600; Alexa Flour
® 
800; Invitrogen).  For all blots, bands were 
visualized and quantitated with an Odyssey scanner and image software (Licor 
Biosciences). Membranes were then stripped with NewBlot stripping buffer (Licor 
Biosciences) for 30 min at 37°C and reprobed with β-actin to serve as the internal control 
for Western blot analyses.  Samples were quantitated, normalized to β-actin and then 
expressed as a fold change. The blots containing protein from purified spermatozoa were 
not reprobed with β-actin as comparisons across samples were examined.  
 
Boar Trials 
  Animals. Experiment 1 was conducted at USMARC in accordance with the 
Animal Care and Use Committee. Mature, Chinese Meishan boars were housed 
individually and fed 6 lb of feed daily with water available ad libitum. Jugular 
catheterization of boars was conducted according to Ford and Maurer (1978), 
approximately 4-5 d prior to initiation of the trial. Experiments 2, 3 and 4 were performed 
at the UNL Animal Science Building. All animal procedures were conducted according 
to the UNL Institutional Animal Care and Use Committee. Mature, white crossbred boars 
were housed individually and fed 5 lb of feed daily with water available ad libitum. At 
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least 3 d before trial initiation, boars were cannulated in the jugular vein according to 
either Barb et al. (1982) or Ford and Maurer (1978).  
  
Materials. D-ala
6
 GnRH-I (Bachem Inc.) and D-ala
6
 GnRH-II (Anygen; 
Gwangju, Korea) were both dissolved in 0.9% sterile saline. SB-75 was synthesized by 
the UNL Protein Core (Lincoln, NE) and dissolved in 0.9% sterile saline. Trptorelix-1 
(Trp-1; Anygen) was dissolved per manufacturer’s instructions. Briefly, Trp-1 was first 
dissolved in 5% dimethylacetamide, mixed with 40% propylene glycol and finally, 
diluted in 55% millipore water.  
 
Experiment 1: GnRH Agonist Trial.  Prior to treatment, blood samples were 
collected every 20 min for 2 h to obtain a baseline hormonal profile. Next, boars (n = 5) 
were given I.V. infusions of either a GnRH-I (D-ala
6
 GnRH-I; 150 ng/kg BW) or GnRH-
II (D-ala
6
 GnRH-II; 150 ng/kg BW) agonist. Blood samples were drawn every 10 min for 
30 min and every 20 min for 270 min thereafter. Blood samples remained at 4°C until 
centrifugation (12,000 x g) and plasma was collected and stored at -20°C until 
radioimmunoassay (RIA) analysis. The experiment was a cross-over design such that 
each boar received each treatment once, 1 wk apart. 
 
Experiment 2: GnRH Antagonist Trial. Prior to treatment, blood was drawn 30 
min and immediately prior to treatment.  Treatments, either a specific GnRH-I (SB-75; 5 
µg biologically active compound/kg BW; n = 9) or GnRH-II (Trptorelix; Trp-1; 5 µg/kg; 
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n = 10) antagonist, were given I.M. in the neck. Each animal also received the vehicle of 
the opposite treatment. Next, blood sampling occurred every 30 min for 3 h (30, 60, 90, 
120, 150 and 180 min) and at 6, 12, 24, 36 and 48 h. Blood samples remained at 4°C until 
centrifugation (2,000 x g) and serum was collected and stored at -20°C until RIA 
analysis. The experiment was a cross-over design such that each boar received each 
treatment once, 1 wk apart. 
 
Experiment 3: SB-75 and GnRH Agonist Trial. First, blood was collected 20 
min, 10 min and immediately prior to treatment. Next, each boar was treated I.M. with 
the GnRH-I antagonist, SB-75 (5 µg biologically active compound/kg BW). 
Approximately 7.5 h later, blood was collected and boars were given I.V. infusions of 
either a GnRH-I (D-ala
6
 GnRH-I; 150 ng/kg BW; n = 5) or GnRH-II (D-ala
6
 GnRH-II; 
150 ng/kg BW; n = 5) agonist. Blood samples were drawn every 10 min for 30 min and 
then every 20 min for 270 min. Blood samples remained at 4°C until centrifugation 
(12,000 x g) and serum was collected and stored at -20°C until RIA analysis. This 
experiment was a crossover design such that each animal received each treatment once, 1 
wk apart.  
 
Experiment 4: Intratesticular GnRH Injection Trial. Blood was collected 20 
min, 10 min and immediately prior to I.V. administration of the anesthetic, sodium 
pentothal (3 mg/lb BW). The use of pentothal as an anesthetic has been previously shown 
not to effect LH or testosterone concentrations in gilts and barrows (Clapper, 2008). Once 
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the animal was sedated, either a GnRH-I agonist (D-ala
6
 GnRH-I; n = 6), GnRH-II 
agonist (D-ala
6
 GnRH-II; n = 6) or saline control (n = 6) was immediately injected 
transscrotally. Each testis was injected 3 times (ventral to dorsal, approximately 2 in 
apart), approximately 1 ½ in into the parenchyma with a 20 gauge, 1 ½ in hypodermic 
needle. The GnRH-I (50 ng) or GnRH-II (50 ng) agonists were dissolved in 1 ml of 
sterile saline, therefore accumulating to a total dose of 300 ng per animal.  Thereafter, 
blood was collected every 10 min for 40 min and every 20 min for 240 min. Blood 
samples remained at 4°C until centrifugation (12,000 x g) and serum was collected and 
stored at -20°C until RIA analysis. This experiment was a crossover design such that each 
animal received each treatment once, 4 d apart.   
 
Radioimmunoassay.  Total testosterone concentrations from explant media were 
determined using a Total Testosterone Coat-a-Count RIA kit (Siemens Healthcare 
Diagnostics, Los Angeles, CA) in accordance with the manufacturer’s instructions. This 
kit has been previously validated in the pig (Oskam et al., 2010; Ashworth et al., 2011) 
and parallelism was confirmed in our lab. The minimum sensitivity of the assay was 0.16 
ng/ml and the intraassay coefficient of variation was 8%. Testicular explant media 
samples were diluted 1:5 with a zero calibrator solution (Siemens Healthcare 
Diagnostics).  
Plasma samples from Experiment 1 were assayed for testosterone at USMARC in 
Dr. Clay Lent’s laboratory according to Ford et al. (2001). The minimum sensitivity of 
the assay was 0.1 ng/ml and the intraassay coefficient of variation between pooled 
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samples averaged 9%. In Experiments 2, 3 and 4, total testosterone concentrations of boar 
serum were measured at UNL using a Total Testosterone Coat-a-Count RIA kit (Siemens 
Healthcare Diagnostics) per manufacturer’s instructions. However, 2 additional standards 
were added to increase the sensitivity of the curve (0.04 and 0.08 ng/ml). Data were 
analyzed and fit to the standard curve using Graphpad PRISM (San Diego, CA) to 
determine relative testosterone concentrations. The minimum sensitivity of the assay was 
0.04 ng/ml and the intraassay coefficient of variation was 10%. LH concentrations for all 
trials were determined by Dr. Clay Lent’s laboratory at USMARC according to Kesner et 
al. (1987).  The minimum sensitivity of the assay was 0.1 ng/ml LH and the intraassay 
coefficient of variation for pooled samples was 10%.  
 
  Statistical Analysis. All data were analyzed using the Statistical Analysis 
System (SAS; Cary, NC). Western blot data were confirmed to be normally distributed 
and analyzed using the GLM procedure with replication as a random effect. Tissue 
explant RIA data was analyzed by the MIXED procedure with replication as a random 
effect.  Statistical evaluations for Experiments 1, 2, 3 and 4 were performed using the 
MIXED procedure with time as a repeated measure. Day of treatment and assay were 
added as random effects. The Shapiro-Wilk test for normality indicated that means for 
RIA data from explant and boar trials were not normally distributed, thus, the means were 
logarithmically transformed and compared using least-significant differences. Non-
transformed means, however, were presented in the Results section for comparison.   
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Results 
 
GnRHR-II is present on the plasma membrane of Leydig cells and germ cells within 
the testis. Since our laboratory previously detected GnRHR-II in the boar testis (data not 
shown), we wanted to determine the location of the GnRHR-II within the testis. 
Following IHC of porcine testicular tissue with an antibody directed against GnRHR-II, 
positive staining was detected in the interstitial compartment, as well as within the 
seminiferous tubules (Fig. 4.1; Panels B-D). Within the interstitium, staining appeared to 
be concentrated on the plasma membrane of Leydig cells. Transmembrane staining was 
also visible within the seminiferous tubules and appeared most intense on germ cells.  In 
contrast, there was no signal detected in control sections incubated without the primary 
antibody (Fig. 4.1; Panel A). The presence of GnRHR-II in the testis was confirmed via 
Western blots using an anti-GnRHR-II antibody. Strikingly, quantification of relative 
band density from Western blots indicated that the testis maintained 6-fold higher 
GnRHR-II protein levels than the anterior pituitary gland (P < 0.0001; Fig. 4.2; Panel A 
and B).  
 
GnRH-II is present in the hypothalamus, anterior pituitary gland and testis. 
Given the abundance of GnRHR-II protein within the testis, we examined tissues for the 
presence of its ligand. An ELISA specific for a precursor form of GnRH-II in pigs was 
used to determine GnRH-II levels in tissue homogenates from the hypothalamus, anterior 
pituitary gland and testis.  Although GnRH-II was detected in homogenates from all 3 
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Figure 4.2. Representative Western blot of porcine anterior pituitary gland and testis tissue (n 
= 5) using an antibody directed against GnRHR-II (Panel A). Quantification of Western blots 
revealed a difference in GnRHR-II protein levels between the tissue types (* P < 0.0001; 
Panel B). 
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tissues, levels were significantly different among tissue types (Fig. 4.3).  Concentrations 
were highest in the testis (1,321 ± 52.5 pg/ml; P < 0.001), intermediate in the anterior 
pituitary gland (393 ± 58.7 pg/ml; P < 0.0001) and lowest in the hypothalamus (220 ± 
67.7 pg/ml; P < 0.0001). Therefore, the abundance of GnRH-II in testicular homogenates 
as well as localization of GnRHR-II on the plasma membrane of Leydig and germ cells 
reflect potential autocrine or paracrine mechanisms controlling testosterone production 
and/or spermatogenesis.  
 
GnRHR-II is localized to the neck region of the spermatozoa tail, corresponding to 
GnRH-II presence in seminal plasma. After our discovery that GnRHR-IIs were 
present on the plasma membrane of germ cells, we screened mature boar spermatozoa for 
GnRHR-II. Western blot analysis of protein from purified boar spermatozoa indicated the 
presence of GnRHR-II (Fig. 4.4; Panel A). Inclusion of testicular protein was used as a 
GnRHR-II positive control based on the results described above. Interestingly, the size of 
GnRHR-II protein bands differed between testis (60 kDa) and spermatozoa (54 kDa). 
Indeed, receptors in sperm can be post-translationally modified differently than other 
tissues, resulting in alternative band sizes (Lee et al., 2000).  Consistent with these 
results, GnRH-II was also detected in the seminal plasma of 7 boars (Fig. 4.4; Panel B). 
Using an ELISA for a precursor form of porcine GnRH-II, concentrations ranged from 
124 to 332 pg/ml, with a mean of 225 ± 27.3 pg/ml.  In point of fact, these values were 
similar to those detected in hypothalamic tissue homogenates (220 ± 67.7 pg/ml). 
Moreover, we utilized immunocytochemistry with an antibody directed against GnRHR-
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Figure 4.3. GnRH-II levels in the hypothalamus, anterior pituitary gland and testis of 
boars. 
a,b,c 
Bars with alternate superscripts differ (P < 0.01). 
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Figure  4.4. Representative Western blot of boar testis and purified spermatozoa protein 
(n = 5) using an antibody directed against GnRHR-II (Panel A). Concentration of 
GnRH-II present in the seminal plasma of boars (n = 7; Panel B).  
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II on live sperm separated by a discontinuous Percoll gradient. Staining was present on 
spermatozoa, localizing to the neck region posterior of the head and at the anterior 
portion of the midpiece (Fig. 4.5; Panels A-C). In contrast, no fluorescent signal was 
detected in secondary only controls (Fig 4.5; Panel D-F). Therefore, the interaction 
between GnRH-II in seminal plasma and its receptor on sperm may be important to 
motility or tail development.  
 
GnRH-II stimulates testosterone production similar to hCG, without upregulating 
LH receptors in testicular explant cultures.  In addition to possible roles in 
spermatogenesis, we also examined the effect of GnRH-II on steroidogenesis in the testis. 
Media was collected from testicular explant cultures pretreated for 1 h with or without 1 
µM GnRH-II followed by treatment with vehicle or 1 I.U. hCG 1 h later. Samples 
collected at 60, 120, 180 and 240 min after pretreatment (GnRH-II or vehicle) were 
assayed for testosterone production by RIA. Treatment values were first normalized to 
basal testosterone levels and expressed as a fold change over the control. There was no 
effect of time or treatment x time interaction for fold change in testosterone concentration 
(P > 0.05). However, there was a significant effect of treatment (P < 0.001), with all 
treatments increasing testosterone over the control treatment (Fig. 4.6). Markedly, the 
GnRH-II pretreatment + no hCG treatment increased testosterone production similar to 
explants that were not pretreated with GnRH-II but treated with hCG (P > 0.05). 
Moreover, Western blot analyses were conducted on testicular explant tissue collected 
after 180 h of culture using antibodies directed against either GnRHR-II or LHR. There 
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Figure  4.5.  Representative confocal microscopy images of boar spermatozoa (n = 5) 
using an antibody directed against GnRHR-II labeled with an Alexa Fluor
®
 488 
secondary antibody (Panels A-C; green). Panels D-F represent secondary only control 
images. 
112 
 
0
0.5
1
1.5
2
2.5
3
Vehicle  hCG Vehicle hCG
F
o
ld
 C
h
a
n
g
e
  
a 
b 
b 
b 
 
 GnRH-II Pretreatment No GnRH-II Pretreatment 
 
Figure 4.6.  Relative testosterone levels secreted by testicular explant cultures (n = 7) 
pretreated with or without 1 µM GnRH-II followed by treatment with vehicle or 1 I.U. 
hCG. 
a,b 
Bars with alternate superscripts differ (P < 0.001). 
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was no difference in the levels of GnRHR-II or LHR protein between treatments (P > 
0.05; Fig. 4.7), suggesting that GnRH-II mediated testosterone production without 
modulating the LH receptor.  
 
GnRH-I and -II promote differential secretion of LH, but not testosterone. After 
establishing that GnRH-II stimulated testosterone production in testicular explant 
cultures, we examined whether GnRH-II would have a similar effect in vivo. Plasma 
collected before and after treatment (10 - 270 min) of mature, Chinese Meishan boars 
with either D-ala
6
 GnRH-I or D-ala
6
 GnRH-II was assayed for LH and testosterone 
concentrations. Mean values were expressed as a fold change over an average of the 
pretreatment values. There was a treatment x time interaction (P < 0.0001) for fold 
change in LH concentrations (Fig. 4.8). Within 10 min after administration of GnRH-I, 
LH concentrations increased 2-fold over pretreatment levels, reaching maximal levels (4-
fold) by 130 min, and remained elevated (3-fold) for the duration of sampling (270 min; 
Fig. 4.8). Similarly, relative LH levels increased 2-fold within 10 min following GnRH-II 
treatment, however, unlike the response to GnRH-I, LH concentrations steadily declined 
to pretreatment values by 110 min (Fig. 4.8).  GnRH-II treated animals had lower LH 
concentrations than males treated with GnRH-I at 210, 230, 250 and 270 min (P < 0.05). 
In addition, LH levels tended to be lower in GnRH-II treated animals compared to those 
in the GnRH-I treatment group at 170 and 190 min (P < 0.10).  
Interestingly, there was no treatment x time interaction for fold change in 
testosterone concentrations (P > 0.05; Fig 4.8). Although there was a significant effect of 
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Figure 4.7. Representative Western blot of porcine explant cultures (n = 7) using an 
antibody directed against GnRHR-II (Panel A) and LHR (Panel B). Quantification of 
Western blots for GnRHR-II (Panel C) and LHR (Panel D) revealed that there were 
no differences between treatments (P > 0.05). 
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Figure 4.8. Relative levels of LH and testosterone after intravenous administration of a 
specific GnRH-I or GnRH-II agonist. After pretreatment (Pre) sampling, treatments were 
administered (arrow). The mean ± SEM values are expressed as a fold change over the 
pretreatment mean. *Different from pretreatment concentrations (P < 0.05; GnRH-I, 
above line; GnRH-II, below line). 
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time (P < 0.0001), GnRH-I and -II induced testosterone levels did not differ from 
pretreatment values at any specific time point (P > 0.05).  Both treatments stimulated a 
similar overall change in testosterone production (P > 0.05). Therefore, testosterone 
secretion was promoted similarly in GnRH-I and -II treatment groups, despite reduced 
LH secretion in GnRH-II treated males. 
 
Testosterone, but not LH, is suppressed in boars treated with SB-75 or Trp-
1.  Since the GnRH-II and -II agonists stimulated testosterone production similarly but 
differed in LH responsiveness, we next utilized a GnRH-II antagonist to determine if 
testosterone could be suppressed without reducing LH secretion. Serum collected before 
and after treatment (10 min - 48 h) of mature, white crossbred boars with either a specific 
GnRH-I (SB-75) or GnRH-II (Trp-1) antagonist was assayed for LH and testosterone 
concentrations. Mean values were expressed as a fold change over an average of the 
pretreatment values. There was no treatment x time interaction for fold change in LH 
levels (P = 0.13), although there was an effect of both treatment (P < 0.01) and time (P < 
0.0001; Fig. 4.9). Trp-1-induced LH levels did not differ from pretreatment levels at any 
time point (P > 0.05). Similarly, SB-75-induced relative LH levels did not differ from 
pretreatment values at any specific time point (P > 0.05).  Overall, Trp-1 stimulated an 
increase in LH secretion compared to SB-75, 1.12 ± 0.08 versus 1.01 ± 0.082, 
respectively (P < 0.001). An overall increase in LH secretion from animals in the Trp-1 
treatment group appears to result from a differential response to treatment after 6 h, 
compared to SB-75 treated animals (Fig. 4.10).  
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Figure 4.9. Relative levels of LH and testosterone after intramuscular administration of a 
specific GnRH-I (SB-75) or GnRH-II antagonist (Trp-1). After pretreatment (Pre) 
sampling, treatments were administered (arrow). The mean ± SEM values are expressed 
as a fold change over the pretreatment mean. *Different from pretreatment concentrations 
(P < 0.05; Trp-1, above line; SB-75, below line). 
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Figure 4.10. Trend lines for relative changes in LH and testosterone concentrations 
following suppression with a specific GnRH-I (SB-75) or GnRH-II (Trp-1) antagonist. 
The mean values are expressed as a fold change over the pretreatment mean.   
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There was an effect of treatment, time and treatment x time interaction (P < 
0.0001) for fold change in testosterone concentration (Fig. 4.9). After treatment with SB-
75, serum testosterone levels were significantly reduced at 3, 6 and 12 h compared to 
pretreatment values. After administration of Trp-1, relative serum testosterone levels 
significantly dropped below pretreatment levels at 6 h and returned to basal levels by 12 
h. Testosterone values for Trp-1 treated animals were higher than boars treated with SB-
75 at 12 and 24 h (P < 0.05).  In addition, testosterone concentration in Trp-1 treated 
boars tended to be higher than animals in the SB-75 treatment group at 6 h (P < 0.10). 
Interestingly, relative testosterone levels returned from suppression similarly between 
SB-75 and Trp-1 treated boars (Fig. 4.10). However, the trend for LH concentration to 
return from suppression was similar to testosterone in animals treated with SB-75, but not 
boars in the Trp-1 treatment group (Fig. 4.10). Thus, the increase in testosterone levels 
following Trp-1 suppression occurred without a corresponding increase in LH secretion. 
 
Antagonizing the GnRHR-I prevents GnRH-II-induced LH secretion. Given 
GnRH-II can function through the GnRHR-I, we developed a trial to evaluate the effect 
of GnRH-I and -II on LH and testosterone production following blockage of GnRHR-Is. 
Serum collected before and after treatment (10 - 270 min) of mature, white crossbred 
boars with SB-75 prior to infusion of either D-ala
6
 GnRH-I or D-ala
6
 GnRH-II was 
assayed for LH and testosterone concentrations. Mean values were expressed as a fold 
change over an average of the pretreatment values. We observed a treatment x time effect 
for fold change in LH concentration (P < 0.0001), as well as significant effects of time (P 
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< 0.0001) and treatment (P < 0.0001; Fig. 4.11). After administration of SB-75, LH 
levels dropped numerically in both treatment groups, but were not significantly different 
from the pretreatment LH concentrations (P > 0.05). After treatment with GnRH-I, LH 
levels rose significantly above pretreatment levels within 10 min and remained elevated 
for 90 min. After treatment with GnRH-II, serum LH concentrations tended to surpass 
pretreatment hormone levels at 10 min (P = 0.07) but not at any other time point (P > 
0.05). At 90 min, relative LH levels tended to be lower in GnRH-II treated animals than 
pretreatment concentrations (P = 0.06) and were significantly lower at 190, 210 and 250 
min (P < 0.05). Compared to LH concentrations after SB-75 treatment, GnRH-I induced 
LH levels were higher from 10 to 170 min (P < 0.05).  Serum LH concentrations 
resulting from GnRH-II treatment rose above post-SB-75 levels at 10 min and remained 
elevated through 50 min (P < 0.05). Fold change in serum LH levels of GnRH-II treated 
animals was lower than GnRH-I treated boars at 10, 20, 30, 50, 70, 90, 110, 150, 170 and 
190 min  (Table 4.1). At 130 min, there was a tendency for lower LH levels in GnRH-II 
treated boars (P = 0.09; Table 4.1). 
We observed an effect of treatment (P < 0.0001) and time (P < 0.0001) but not a 
treatment x time interaction (P = 0.74) for fold change in testosterone concentrations 
(Fig. 4.11). After treatment with SB-75, testosterone levels for both GnRH-I and -II 
treatment groups dropped significantly below pretreatment levels, remaining suppressed 
for 20 min before returning to basal levels (P < 0.05; Fig. 4.11). Compared to post-SB-75 
levels, testosterone concentrations were significantly elevated at 50, 70, 90, 110, 130, 
150, 170, 190, 210, 230 and 250 min following GnRH-I stimulation. Further, there was a 
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TABLE 4.1. MEAN FOLD CHANGE FOR LH CONCENTRATIONS ± SEM 
FOLLOWING TREATMENT WITH A GnRH-I ANTAGONIST (SB-75) AND 
SUBSEQUENT INFUSION OF AGONISTS FOR GnRH-I OR -II
a
. 
Time Post-Treatment 
(min) 
D-ala
6
 GnRH-I D-ala
6
 GnRH-II Significance 
10 2.95 ± 0.23 1.64 ± 0.25 P = 0.0228 
20 3.22 ± 0.31 1.56 ± 0.25 P = 0.0041 
30 2.80 ± 0.25 1.29 ± 0.24 P < 0.0001 
50 2.57 ± 0.23 0.97 ± 0.24 P < 0.0001 
70 2.17 ± 0.23 0.76 ± 0.25 P < 0.0001 
90 1.91 ± 0.25 0.64 ± 0.25 P < 0.0001 
110 1.68 ± 0.25 0.79  ± 0.27 P = 0.0009 
130 1.49 ± 0.23 0.87 ± 0.27 P = 0.0889 
150 1.33 ± 0.25 0.59 ± 0.31 P = 0.0141 
170 1.43 ± 0.31 0.69 ± 0.25 P = 0.0420 
190 1.01 ± 0.27 0.58 ± 0.23 P = 0.0251 
210 0.93 ± 0.25 0.54 ± 0.25 P = 0.1469 
230 0.93 ± 0.23 0.57 ± 0.27 P = 0.9630 
250 0.74 ± 0.31 0.51 ± 0.25 P = 0.2733 
270 0.99 ± 0.25 0.64 ± 0.31 P = 0.6012 
a   
Values are expressed as a fold change over the pretreatment levels.  
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Figure 4.11. Relative levels of LH and testosterone after intramuscular administration 
of SB-75 and intravenous treatment with a specific GnRH-I or GnRH-II agonist. After 
pretreatment (Pre) sampling, SB-75 was administered prior to blood collection (black 
arrow). Approximately 7.5 h later, blood was collected and treatments were 
administered (Post; gray arrow). The mean ± SEM values are expressed as a fold 
change over the pretreatment mean. *Different from pretreatment concentrations (P < 
0.05; GnRH-I, above line; GnRH-II, below line). 
 
-1
0
1
2
3
4
P
re
P
o
st 1
0
2
0
3
0
5
0
7
0
9
0
1
1
0
1
3
0
1
5
0
1
7
0
1
9
0
2
1
0
2
3
0
2
5
0
2
7
0
F
o
ld
 C
h
a
n
g
e
 
Time (min) 
0
1
2
3
4
P
re
P
o
st 1
0
2
0
3
0
5
0
7
0
9
0
1
1
0
1
3
0
1
5
0
1
7
0
1
9
0
2
1
0
2
3
0
2
5
0
2
7
0
F
o
ld
 C
h
a
n
g
e
 
D-ala⁶ GnRH-I 
D-ala⁶ GnRH-II 
trt P < 0.0001 
time P < 0.0001 
trt*time P < 0.0001 
trt P < 0.0001 
time P < 0.0001 
trt*time P = 0.7417 
* * 
* 
* 
* 
* 
* 
* * * 
* * 
Testosterone 
* * * 
LH 
123 
 
tendency for increased testosterone levels at 270 min (P = 0.08).  Following GnRH-II 
treatment, relative testosterone levels were increased at 50, 70, 90, 110, 130, 150 and 170 
min (P < 0.05) compared to post-SB-75 hormone concentrations,. In addition, there was a 
tendency for elevated testosterone levels at 190 min (P = 0.08). Overall, GnRH-I 
stimulated a higher level of relative testosterone production, (1.16 ± 0.28) compared to 
GnRH-II (0. 73 ± 0.28; P < 0.05). In summary, treatment with a GnRH-I antagonist 
prevented GnRH-II, but not GnRH-I, induced LH secretion. 
 
Intratesticular injection with GnRH-II increases serum testosterone, but not 
LH production.  Finally, we designed an experiment to test whether direct 
administration of GnRH-II into the testis would elicit differential results than systemic 
delivery. Serum collected before and after intratesticular treatment (10 - 240 min) of 
mature, white crossbred boars with either saline (control), D-ala
6
 GnRH-I or D-ala
6
 
GnRH-II was assayed for LH and testosterone concentrations. Mean values were 
expressed as a fold change over an average of the pretreatment values. There was not a 
significant treatment x time interaction (P = 0.63) or an effect of time (P = 0.48) for fold 
change in LH concentrations (Fig. 4.12). However, there was an effect of treatment (P < 
0.0001). GnRH-I induced an increase in LH secretion (1.46 ± 0.16) compared to control 
animals (1.13 ± 0.17), whereas GnRH-II treatment had no effect (P > 0.05; Fig. 4.12). 
Similarly, there was no effect of time (P = 0.93) or treatment by time interaction (P = 
0.11) for testosterone fold changes. Like LH, GnRH-I stimulated significantly higher 
testosterone production (1.74 ± 0.22) than GnRH-II (1.15 ± 0.22) or saline (0.67 ± 0.22). 
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Figure 4.12. Relative levels of LH and testosterone after intratesticular administration of 
saline (control), GnRH-I agonist or GnRH-II agonist. The mean ± SEM values are 
expressed as a fold change over an average of the pretreatment mean. There was a 
significant treatment effect but no effects of time or treatment x time interaction for either 
hormone. 
a,b,c 
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0.5
1
1.5
2
Control GnRH-I GnRH-II
F
o
ld
 c
h
a
n
g
e
 
a 
b 
a 
0.5
1
1.5
2
Control GnRH-I GnRH-II
F
o
ld
 C
h
a
n
g
e
 
a 
b 
c 
trt P < 0.0001 
time P = 0.4831 
trt*time P = 0.6296 
trt P < 0.0001 
time P = 0.9280 
trt*time P = 0.1079 
Testosterone 
LH 
125 
 
Notably, the GnRH-II stimulated testosterone secretion was also higher (P < 0.001) than 
controls (Fig. 4.12). In conclusion, intratesticular injections of GnRH-II stimulated 
testosterone production in the absence of LH synthesis. 
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Discussion 
 
This study is the first to elucidate a specific function for GnRH-II and its receptor 
in the testis of boars. First, we discovered 6-fold more GnRHR-II protein in the testis 
compared to the anterior pituitary gland. Similarly, Millar et al. (2001) demonstrated that 
the marmoset testis expressed the highest level of GnRHR-II mRNA compared to any 
other tissue, including the anterior pituitary gland. In the current study, GnRH-II was 
detected in tissue homogenates of the hypothalamus, anterior pituitary gland and testis of 
the boar. Indeed, GnRH-II mRNA has been detected in the hypothalamus (Miyamoto et 
al., 1984; Lescheid et al., 1997), pituitary (Mongiat et al., 2006) and testis (Mongiat et al., 
2006; An et al., 2008) of other species.  However, this is the first report of GnRH-II in 
pig tissues. Interestingly, GnRH-II levels were significantly elevated in the testis 
compared to the other tissue types, suggesting a specific biological role for local 
production of GnRH-II.  
Immunohistochemistry revealed the presence of GnRHR-II on the plasma 
membrane of Leydig cells. The presence of GnRHR-IIs on Leydig cells has implications 
for a direct role in steroidogenesis. Indeed, boars immunized against GnRH-II displayed 
reduced testosterone concentrations, whereas LH levels were unaffected (Bowen et al., 
2006). Similarly, primary Leydig cell cultures from GnRH-II immunized boars failed to 
produce testosterone similar to control animals following LH challenge. Moreover, 
treatment with the specific GnRH-I antagonist, SB-75, mitigated the response of porcine 
Leydig cells to hCG stimulation (Zanella et al., 2000). Given that boars lack the testicular 
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GnRHR-I, the discovery of the GnRHR-II on porcine Leydig cells may further explain 
the results of these studies.  
Concurrently, we identified positive staining for the GnRHR-II on germ cells in 
the boar testis via IHC and confirmed this discovery by Western blot.  Interestingly, the 
band size differed between testis (60 kDa) and spermatozoa (54 kDa) samples. While 
Eicke et al. (2005) also detected marmoset GnRHR-II protein at 54 kDa in the ovary, this 
variation in band size may be due to alternative post-translational modifications in 
different cell types.  For example, the GnRHR-I has been shown to have a molecular 
mass of 50-60 kDa in the anterior pituitary gland, whereas the GnRHR-I present on 
mature sperm has a band size of 45 kDa (Lee et al., 2000).  Specifically, glycosylation 
events have been reported in the sperm maturation process for numerous species 
including boars (Topfer-Petersen et al., 1990).  Therefore, the alternative band size we 
detected may indicate differential modification of the GnRHR-II on mature sperm.  
In the current study, the GnRHR-II was localized on spermatozoa via 
immunocytochemistry. Interestingly, the signal was detected in the neck region of the 
tail, just posterior to the head and at the anterior portion of the midpiece. While the 
precise function of the GnRHR-II in this region is still unknown, its anatomical location 
indicates that it could be important for a number of sperm functions including 
fertilization, motility, the acrosome reaction and capacitation. For example, the GnRHR-
II may interact with the sperm centrosome, which is required for fertilization of the 
oocyte and embryonic development in many species, like humans (Sathananthan et al., 
1996), sheep (Crozet, 1990), and pigs (Szollosi and  Hunter, 1973). In addition to well 
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characterized roles in motility (Buffone et al., 2012), the tail may act as a sensory cilium 
(Bloodgood, 2010), detecting alterations in the environment and initiating signals that 
could influence the acrosome reaction (Buffone et al., 2012). Moreover, calcium 
mobilization is a key contributor to sperm capacitation and intracellular stores are 
released from the redundant nuclear envelope, located in the neck region of sperm (Ho 
and  Suarez, 2003). In fact, an inositol 1,4,5-trisphosphate (IP3) receptor-gated calcium 
store is released from the base of the flagellum prior to hypermotility, however, the 
receptor mediating this action has not yet been identified (Ho and  Suarez, 2003). 
Interestingly, our laboratory also detected GnRH-II in the seminal plasma of boars, 
further indicative of a role for the GnRHR-II on sperm. While the presence of GnRH-II in 
seminal plasma has not been examined previously, GnRHR-II mRNA has been detected 
in the human and marmoset uterus, oviduct and the ovary (Neill et al., 2001; Millar et al., 
2001). Thus, sows and gilts may maintain functional GnRHR-IIs within the reproductive 
tract that could interact with GnRH-II in the seminal plasma of boars.  
Here we also demonstrated that porcine testicular explants have the capacity to 
elicit testosterone production. This finding is in agreement with many previous studies in 
other species, as well as the pig (Stewart and  Raeside, 1976; Zanella et al., 2000; Oatley 
et al., 2004; Lambrot et al., 2006; Hallmark et al., 2007). We observed that short-term 
treatment with GnRH-II stimulated testosterone secretion to the same level as hCG, 
indicating that GnRH-II is an effective stimulator of testosterone synthesis directly at the 
testis. However, treatment with GnRH-II prior to hCG did not elicit a synergistic effect 
on testosterone synthesis, suggesting that GnRH-II is not acting through the LHR. This 
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was confirmed by Western blot analysis, as the quantity of LHR protein remained 
consistent across treatments. However, it is important to note that tissues were collected 3 
h after GnRH-II treatment in our study. In rats, upregulation of the LHR required 
between 3 and 6 h after a single dose of hCG (1-10 µg; Dufau et al., 1984). Thus, LHR 
upregulation may have occurred with an extended culture period.  
In the present study, boars challenged with GnRH-I and -II demonstrated 
differential LH secretion over time. It is well known that GnRH-I stimulates LH secretion 
in the boar (Wise et al., 1996). Additionally, high doses of GnRH-II can stimulate low 
levels of LH production in other species (Millar and  King, 1983; Millar et al., 1986). 
However, this effect is likely mediated through interaction with the GnRHR-I, as 
administration of a GnRH-I antagonist attenuates GnRH-II induced gonadotropin 
secretion (Densmore and  Urbanski, 2003; Okada et al., 2003; Kauffman et al., 2005). In 
the current study, LH is produced but markedly reduced in GnRH-II treated boars, 
suggesting GnRH-II may have activated the GnRHR-I in the anterior pituitary gland. 
Despite reduced LH levels, testosterone concentrations in boars treated with GnRH-II 
mirrored levels seen in GnRH-I treated animals. This discrepancy indicates that GnRH-II 
may mediate its action directly at the testis.  
Next, boars were treated with a specific GnRH-I (SB-75) or GnRH-II (Trp-1) 
antagonist. In fact, this is the first in vivo examination of Trp-1 on the HPG axis. 
Compared to pretreatment levels, LH was not significantly suppressed in either treatment 
group. Although, SB-75 induced, LH suppression has been demonstrated in boars at 
doses of 5 (Wise et al., 2000), 10 (Zanella et al., 2000) and 20 µg/kg BW (Wise et al., 
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2000), recent experimental (Horvath et al., 2004) and clinical (Gonzalez-Barcena et al., 
1994; Comaru-Schally et al., 1998; Drewa and  Chlosta, 2009) trials demonstrated that 
low doses of SB-75 may cause only partial suppression of the HPG axis (Rick et al., 
2011). Therefore, the lack of SB-75 induced, LH suppression demonstrated in this trial 
may be a reflection of the dose utilized or differing experimental conditions. The effects 
of Trp-1 on LH secretion have not been previously examined, but in the current study 
Trp-1 treatment did not impact LH production. This finding may support the hypothesis 
that GnRHR-II is not involved in gonadotropin secretion in the boar, as suggested in 
other species (Densmore and  Urbanski, 2003; Okada et al., 2003; Schneider 
and  Rissman, 2008). 
In contrast, SB-75 reduced testosterone production at 3, 6 and 12 h post-
treatment, consistent with reports that maximal testosterone suppression was achieved at 
8-12 h following SB-75 treatment (Behre et al., 1992; Klingmuller et al., 1993). 
Interestingly, reduced testosterone levels at these time points were not correlated with 
LH. Perhaps SB-75 elicited its effects at the level of the testis, given that it can bind the 
GnRHR-II with low affinity (Maiti et al., 2003).  Although suppression of testosterone 
release only occurred at 6 h post-treatment, Trp-1 mediated this reduction without 
affecting LH. Furthermore, the patterns of LH and testosterone return from suppression 
were similar in SB-75 treated animals, whereas testosterone levels increase post-Trp-1 
suppression without a corresponding increase in LH. This differential action of Trp-1 
compared to SB-75 may suggest it mitigates testosterone secretion via alternative 
mechanisms. Perhaps GnRHR-II mediates testosterone synthesis in a constitutive manner 
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in the testis and antagonizing basal production only moderately reduces serum 
testosterone concentrations. 
In the current report, we also pretreated boars with SB-75 prior to administration 
of GnRH-I or -II agonists. After GnRH-I treatment, SB-75 was unable to suppress LH or 
testosterone release. This discovery may be related to competition for binding sites 
between SB-75 and GnRH-I. SB-75 functions, in part, through occupancy of the 
GnRHR-I (Halmos et al., 1996), therefore a bolus of competing high affinity ligand 
(GnRH-I) may have displaced SB-75 from the GnRHR-I (Ron-El et al., 2000; Fauser et 
al., 2002).  In fact, this phenomenon is utilized frequently in women to prevent ovarian 
hyperstimulation syndrome during assisted reproduction procedures (Olivennes et al., 
1996). Women pretreated with SB-75 experienced reduced LH levels, although 
administration of GnRH-I increased LH levels significantly in all 30 patients within 30 
min (Felberbaum et al., 1995). After infusion of GnRH-II, relative LH levels did not 
increase above pretreatment concentrations, suggesting that GnRH-II, unlike GnRH-I, 
was unable to displace SB-75 from the GnRHR-I. Indeed, GnRH-II has 10-fold lower 
affinity for the GnRHR-I than GnRH-I (Neill, 2002) and therefore, presumably lacks the 
binding affinity needed to displace SB-75. Interestingly, testosterone was produced in a 
manner consistent with GnRH-I treatment, suggesting testosterone production occurred 
independent of LH. This finding is in agreement with other studies who demonstrated 
testosterone can be regulated in the boar without affecting LH secretion (Zanella et al., 
2000; Bowen et al., 2006).  
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In our final experiment, we injected saline, GnRH-I or GnRH-II directly into the 
testis of sedated boars. Here, we demonstrated that intratesticular administration of 
GnRH-I can stimulate LH and testosterone secretion, suggesting that GnRH-I was able to 
travel through the blood to the anterior pituitary gland.  However, a much lower dose of 
each agonist was utilized in this trial compared to Experiment 1 (300 ng/boar versus 150 
ng/kg BW, respectively). Consistent with this, intratesticular injection of rats (which have 
testicular GnRHR-Is; Sharpe and  Cooper, 1987) with 1 ng of a GnRH-I agonist 
stimulated testosterone, but not LH secretion, whereas a 10 ng injection of GnRH-I 
significantly elevated both LH and testosterone (Sharpe et al., 1983). These results 
indicated that lower doses of GnRH-I can stimulate steroidogenesis independent of LH, 
however, higher doses can be transported through the blood to the anterior pituitary 
gland. In our experiment, GnRH-II did not stimulate LH release, even though it 
presumably traveled through the blood like GnRH-I. Despite this, GnRH-II was able to 
stimulate testosterone synthesis, suggesting it had a direct testicular effect.  
Taken together, these data indicate that, as in other species, the predominant 
function of GnRH-II and its receptor in the boar does not appear to be gonadotropin 
secretion. The interaction between GnRH-II and the GnRHR-II appears to elicit 
testosterone synthesis in an autocrine or paracrine manner, without production of LH by 
the anterior pituitary gland. However, further studies utilizing hypophysectomized boars 
might be necessary to completely delineate the action of GnRH-I versus GnRH-II.  
Physiologically, it appears GnRH-II may play a role in constitutive regulation of 
testosterone production in the testis. This effect may be required to support 
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spermatogenesis synergistically with the pulsatile action of LH. Moreover, the discovery 
of GnRHR-II on boar spermatozoa as well as GnRH-II in seminal plasma may reflect a 
role in spermatogenesis or sperm function.  
In conclusion, this study is the first demonstration of a specific function for the 
GnRHR-II in the testis. Differential regulation of testosterone secretion could lead to 
advancements in human fertility treatments, contraceptives, cancer research or 
pharmacological agents. Moreover, novel screening methods could be utilized in boar 
studs to improve reproductive efficiency. Eliminating infertile or subfertile boars from 
the herd early will reduce the economic losses associated with rearing and training. 
Furthermore, the discovery of GnRHR-II on sperm and GnRH-II in seminal plasma may 
potentially lead to the development of innovative strategies to improve conception rates 
on the sow farm. Implementation of these new technologies could lead to enhanced 
productivity and profitability of pork producers.  
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Appendix I 
 
Boar Cannulation Procedures 
 
Preparation. Prior to Cannulation, 1.5 m of tygon microbore tubing (ID 0.050 in, 
OD 0.090 in, Wall 0.020 in, formulation S-54-HL) was cut and pretreated with 
tridodecylmethylammonium chloride (TDMAC; Polysciences, Inc., Warrington, PA). 
Briefly, about 10 ml of TDMAC was poured into a 100 ml beaker secured with a ring 
stand. Care was taken to constantly keep the TDMAC covered with Saran™ wrap as it 
evaporates quickly (do not perform in hood). Next, about 30 cm of the tubing was 
submerged and a 10 ml syringe was used to draw up TDMAC into the entire cannula for 
2 min. Finally, the TDMAC was flushed out with 100 ml of air and allowed to dry for 2 
d. After drying, the cannula (at the end that was submerged in TDMAC) was well marked 
with sharpie at 18, 24 and 30 cm and placed into a gas sterilization bag with an adapter 
(18 gauge needle with 2/3 of the needle cut off with a Dremel tool) and stopper (1 ml 
syringe cut off and melted at 0.3 ml) attached loosely. Cannula packs were then gas 
sterilized at the University of Nebraska Medical Center sterile processing lab (Omaha, 
NE). 
 
Non-Surgical Cannulation. Boars were non-surgically cannulated according to 
Barb et al. (1982). Boars were snared by use of both a rope and mechanical snare. The 
neck was exposed and cleaned with Betadine spray.  Next, a sterilized 11 gauge needle 
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with vet hub was inserted into the neck until blood was apparent on drawback with a 20 
ml luerlock syringe.  Then, the syringe was removed and the sterile cannula was threaded 
through the needle into the jugular vein. Testing the cannula for blood occurred 3 times 
as threading progressed (at approximately 18, 24 and 30 cm) using a 10 ml syringe filled 
with 3.5% sodium citrate. Once fully inserted, the needle was removed, the adapter was 
secured to the tubing with small, thin strips of duct tape and the cannula was flushed 
again with 5 ml of a sterile heparinized saline solution (0.9% NaCl, 500 units heparin, 1% 
benzyl alcohol, 5,000 units penicillin; pH 7.4) and capped. Next, the cannula was coiled 
up and inserted into a 3.5 x 4 in duct tape pouch.  Finally, the cannula and pouch would 
be secured to the animal by wrapping the chest area twice around with 4 in Elastikon 
adhesive tape followed by 4 in duct tape. Banamine (2 mg/kg BW) and procaine 
penicillin (300,000 units/lb BW) were given intramuscularly to minimize pain and 
inflammation. After insertion, blood clotting was prevented by daily catheter infusions 
with approximately 10 ml of 3.5% sodium citrate and 3 ml of heparinized saline solution.   
 
Surgical Cannulation.  Boars were surgically cannulated according to Ford 
and  Maurer (1978).  Briefly, boars were sedated with 5 ml of a telazol, atropine, rompun 
and ketamine (TARK; 0.2 mg/kg atropine, 0.8 mg/kg rompun, 3.1 mg/kg ketamine and 
0.8 mg/kg telazol) mixture, I.M. in the neck. Then, animals were given an additional 3 ml 
TARK (0.1 mg/kg atropine, 0.5 mg/kg rompun, 2.1 mg/kg ketamine and 0.5 mg/kg 
telazol) intravenously via an ear vein.  Once anesthetized, the animal was placed onto the 
surgery cart in a dorsal recumbent position and the surgical site (ventral cervical area) 
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was prepared by removing hair with clippers, performing a Betadine scrub and shaving 
with a razor. The site was then disinfected with 3 Betadine scrubs and water removed 
with 70% isopropyl rubbing alcohol swabs. The front feet were covered with plastic O.B. 
gloves and restrained with rope to each side of the animal. Nose tubes were inserted into 
each nostril and secured before administration of the inhalant anesthetic isoflurane (3.5%) 
and oxygen (0.7 L/min).  
Hereafter, surgical cannulation was performed according to Ford and  Maurer, 
(1978).  Using sterile gloves, a 1 cm skin incision was made approximately 4-8 cm 
anterior to the manubrium sterni and 4-5 cm lateral to the left side of the midline, 
exposing the cervical musculature and subcutaneous tissue. Blunt dissection was 
performed until the approximate location of the external jugular vein was palpable. The 
vein was then punctured with an 11 gauge, 3 in needle (short beveled, thin walled) with 
vet hub attached to an empty 3 ml slip tip syringe.  Once blood was evident upon 
drawback, the needle was removed and a 1.5 m sterilized catheter filled with 3.5% 
sodium citrate was inserted slowly into the vein.  During insertion, the presence of blood 
was confirmed 3 times to ensure adequate catheter function using a 10 ml syringe filled 
with 3.5% sodium citrate attached to the catheter and a 17 gauge female luer adapter.  
After insertion, the animal was moved to a right lateral recumbent position on the 
cart, exposing the back.  Care was taken to hold the catheter in place during the move.  
The left ventral side of the neck and down to the scapula was clipped of hair.  The site 
was then washed with Betadine and cleared with 70% alcohol swabs.  Next, a 30 cm long 
stainless steel cannula containing a trocar was inserted into the previous incision adjacent 
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to the catheter.  It was then passed dorsally through the lateral musculature to a midway 
point between the neck and back.  The trocar was exteriorized using another 1 cm 
incision.  Next, the trocar was removed, leaving the hollow stainless steel cannula. The 
loose end of the catheter was then passed through the cannula, and the cannula was 
removed from the tissue.  The process was repeated from the midpoint of the neck to the 
back, such that the free end of the catheter was exteriorized in a final location anterior to 
the scapula.  During the cannulation process, the catheter was continually tested to ensure 
function was retained.  The 1st and 2nd incisions were then sutured closed with non-
dissolvable suture.  
Next, protective tubing (termed a collar) was placed around the catheter to anchor 
it to the animal.  The collar was made by inverting a 2.54 cm of amber rubber tubing (ID: 
3.2 mm, OD: 6.4 mm) back on itself and secured together with 20 cm of suture. Once the 
collar was placed around the catheter, the animals head was flexed towards the sternum 
and the sutures from the collar were secured to the animal directly over the last incision, 
using a surgical needle.  The collar was then adhered to the catheter with a few drops of 
cyclohexanone at both openings of the collar.  Next, the collar-catheter complex was 
further adhered to the animal at the exteriorization point with aquarium silicone 
(containing acetic acid; Marineland, Blacksburg, VA) to prevent bacterial contamination 
of the incision.  The catheter was checked once more, flushed with 5 ml of 3.5% sodium 
citrate and 5 ml of heparinized saline and stoppered.  The catheter was secured further by 
adhering 4 in Elastikon adhesive strips to the animal with hip tag cement. Strips were 
adhered ~1 cm to the right and left of the catheter (12 in strips), as well as 1 cm from the 
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top and bottom (7 in strips) of the catheter.  One final strip was placed over the catheter, 
taking care to keep the tag cement on the tape surrounding the catheter.  Finally, each 
animal was injected with (I.M.) with 3 ml of Polyflex (8.8 mg/kg; Fort Dodge Animal 
Health, Fort Dodge, IA) and 2 ml of Banamine (2 mg/kg; Schering-Plough Animal 
Health Corp., Union, NJ). 
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